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Abstract 
Introduction 
Prader- Willi syndrome (PWS) is a genetic condition commonly associated with 
hyperphagia and obesity. PWS is thought to have hypothalamic dysfunction which is the 
head ganglion of autonomic nervous system (ANS). In current literature, ANS is believed 
to be defective in PWS. ANS may also have a role in controlling orexigenic hormone 
ghrelin and energy expenditure.  One study reported higher resting energy expenditure 
adjusted for lean body mass in growth hormone naive PWS group but another study found 
lower activity associated energy expenditure compared to controls. Other studies found 
adjusted basal and sleeping metabolic rates were not different to the controls. Complete 
profile of energy expenditure in PWS remains unclear. 
We hypothesize that there is defective ANS in PWS, as a result of hypothalamus 
dysfunction, and it leads to high orexigenic hormone, acyl ghrelin, and low energy 
expenditure that in turn cause obesity. 
 
Methods 
We compared the ANS functions, acyl ghrelin status and energy expenditure in children 
with PWS and controls.  
We recruited 16 genetically- confirmed children with PWS and 16 controls. Exclusion 
criteria were diabetes mellitus, psycho-trophic medications, and other hypothalamic 
pathologies.  
We performed a mixed meal challenge to assess ANS function and acyl ghrelin status of 
PWS and control groups. We used Bodystat 1500® to measure body composition.  
Orthostatic hypotension, due to gravity, stimulates baroreceptors and activates 
sympathetic nervous system to counter regulate postural drop in blood pressure by 
increasing pulse rate, stroke volume and vasoconstriction. We used orthostatic change in 
pulse rate (PR), blood pressure (BP), and mean arterial pressure (MAP) expressed as per 
cent change of PR (%ΔPR), BP (%ΔBP), and MAP (%ΔMAP) from lying to standing to 
access sympathetic nervous function. ANS was further stimulated by a mixed meal and we 
examined %ΔPR, %ΔBP, and %ΔMAP at 15 and 30 seconds after standing from 
recumbent position; at fasting, and post-prandial periods. We also measured plasma 
gastrin, catecholamines (Pcat) and urinary catecholamines (Ucat) at fasting and post- 
prandial periods to complement autonomic cardiovascular data. Using Actiheart®, we 
compared weight and fat free mass adjusted total, resting, activity- associated and non- 
exercise associated thermogenesis between two groups. 
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Results 
PWS group was younger, shorter, and had reduced lean mass than the controls. Post-
prandial %ΔPR at both 15 and 30 seconds were significantly lower in PWS group than 
controls. The difference in %Δ systolic BP and diastolic BP did not reach statistical 
significance but %ΔMAP at 60 min and 120 min after meal was significantly lower in PWS. 
Postprandial plasma gastrin and Ucat were higher in PWS group than controls but Pcat 
were not different in two groups. Fasting plasma acyl ghrelin (AG) was significantly higher 
in PWS but it decreased to similar level of controls at 60 and 120 minutes after a meal. 
The rate of fall of plasma acyl ghrelin was faster in the PWS group than the controls. 
Fasting AG is negatively correlated to fasting %ΔPR at 30s (r value -0.52, p= 0.04). 
When adjusted for both weight and fat- free- mass, PWS group had lower total, resting, 
activity- associated and non- exercise associated thermogenesis than the controls.  
 
Conclusions 
We report that there is dysautonomia, high fasting acyl ghrelin and low energy 
expenditures in children with PWS. 
In PWS, there is reduction in GABA-A receptor number and its actions as a result of the 
deleted genes of 3, 5, and 3 subunit of GABA-A receptors in the PWS gene region; 
and probable exaggerated GABA-B receptors actions due to effect of compensatory 
hyper-- amino- butyric- acidaemia on the normal GABA-B receptors. The abnormities lead 
to GABA system dysfunction in PWS. GABA is the key neurotransmitter between Nucleus 
Tractus Solitarius and C1 neurons that connect to the thoracic spinal cord that sends 
efferent neurons to sympathetic ganglions. GABA system dysfunction, therefore, may be 
the cause of sympathetic failure. Moreover, GABA is generally an inhibitory 
neurotransmitter and GABA dysfunction may be the cause of poor vagal inhibitory function 
that lead to high post-prandial plasma gastrin production, and increased catecholamine 
production from adrenal medulla probably by increase chromaffin cells gap junction 
communications. Our findings of dysautonomia can be explained by GABA dysfunction in 
PWS. Dysautonomia may also be the cause of high fasting acyl ghrelin and low energy 
expenditures. Therefore in PWS, there is imbalance in energy intake and expenditure 
resulting in obesity. 
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Chapter 1: Introduction and hypothesis 
 
1.1: Prader- Willi Syndrome (PWS) 
Prader- Willi Syndrome (PWS) is a chromosomal disorder and it is one of the common 
genetic causes of obesity (Prader, Labhart et al. 1956, Cassidy and Driscoll 2009). It is 
due to the result of deletion of paternal chromosome 15q11.13 in 75 % of PWS (Butler 
1990, Bittel and Butler 2005). Typical deletions in PWS occurs at either breakpoint 1 (BP1; 
located between 18.68 and 20.22Mb) or break point 2 (BP2; located between 20.81 and 
21.36 Mb) at the centromeric end with the resulting genetic subtypes designated as type I 
or type II deletions, respectively. Regardless of whether the deletion begins at BP1 or BP2, 
typical deletions generally end at break point 3 (BP3, located between 25.94 and 27.28 
Mb) at the telomeric end of the 15q11-q13 region (Butler, Fischer et al. 2008) (Figure 1). 
 
Figure 1: Genetic map of human chromosome 15q11-13 adapted from (Cassidy and 
Driscoll 2009, Rout, Abdul-Rahman et al. 2012). Type I deletion is from BP1 to BP3 and 
type II deletion from BP2 to BP3. Both type I and II deletions in PWS involve GABA-A 
receptor subunit genes. Gene number 1 to 12 represents MKRN3, MKRN3-AS, MAGEL2, 
NCD, C150RFN, SNURF-SNRPN, IPW, UB3A-AS, UBE3A, ATP10A, OCA2, and HERC2 
respectively. UBE3A and ATP10A are maternally expressed and linked with Angelman 
syndrome whereas the rest of the genes are paternally expressed and linked with PWS. 
Imprinting center (IC) is both maternally and paternally expressed. Small nucleolar RNA 
(snoRNA) contains non- coding RNA such as snord115 and116. 
 
Normally the maternal copy of chromosome 15 is inactivated and the paternal copy is 
expressed. PWS results when active paternal copy is absent (Nicholls, Knoll et al. 1989). 
Twenty percent of PWS is due to maternal uni- parental disomy and 5% due to imprinting 
center defect at paternal chromosome 15q11(Robinson, Bottani et al. 1991, Bittel and 
Butler 2005) (Figure 2). Maternal uniparental- disomy is thought to occur due to an earlier 
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embryonic trisomy 15 (two copies of maternal chromosomes 15 and a copy of paternal 
chromosome 15) followed by trisomy rescue leaving only two copies of maternal 
chromosome 15. Microdeletion in the imprinting center, which controls the imprinting 
process within 15q11.13, also leads to development of PWS (Bittel and Butler 2005). The 
genetic diagnosis for PWS is made by methylation tests, fluorescence in-situ hybridization 
test (Cassidy and Driscoll 2009), or, more recently, by methylation- specific multiplex 
ligation- dependent probe amplification (Henkhaus, Kim et al.). Methylation test identifies if 
the paternal copy of 15q11 is inactivated, and fluorescence in-situ hybridization test 
examines presence or absence of paternal copy of 15q11 or presence of two maternal 
copies of 15q11. Methylation- specific multiplex ligation- dependent probe amplification 
(MS- MLPA- PWS/AS kit from MRC- Holland, Amsterdam, Netherlands) has original kit A1 
(25 probes) that is used to detect methylation status and deletion subtypes in individuals 
with PWS. The newer kit B1 (32 probes) is used for additional information such as 
imprinting center mutation and adjoining small non- coding RNAs microdeletions 
(Henkhaus, Kim et al.).  
Within the PWS region, there are twelve genes involved, namely small nuclear 
ribonucleoprotein N (SNURF-SNRPN), makorin-3 (MKRN3 or ZNF127), necdin (NCD) and 
mage-like 2 (MAGEL-2), MKRN3-AS, C150RFN, imprinted in PWS (IPW), ubiquitin- 
protein ligase E3A (UB3A-AS), occulo- cutaneous albinism 2 (OCA2), and HECT domain 
and RCC1- like domain 2 (HERC2) (Cassidy and Driscoll 2009). The genes encode 
proteins if paternal allele is expressed (Runte, Huttenhofer et al. 2001). A recent work on 
Snord116del mice showed the long non-coding RNA (lncRNA) in PWS region has 
regulatory function on gene encoding diurnal rhythm and metabolism (Zhang, Bouma et al. 
2012, Powell, Coulson et al. 2013). PWS may be the first human disease that non-coding 
gene has a role in pathogenesis.  
The incidence of PWS by genetic diagnosis in Australia was 1: 25,000 live birth in a study 
done between 1998 to 2000 (Smith, Egan et al. 2003). In Anglia and Oxford health regions 
of United Kingdom, the incidence rate was 1: 29,000 live births and the prevalence was 1: 
52,000 (Whittington, Holland et al. 2001). In Belgium, the incidence was reported as 1: 
26,676 live births and the prevalence 1: 76,574 (Vogels, Van Den Ende et al. 2004).  
The common clinical features of PWS include diminished foetal movement during 
pregnancy, hypotonia, initial poor feeding and failure to thrive, poor growth, developmental 
delay, hypogonadotrophic hypogonadism, central hypothyroidism, hypopigmentation, 
small hands and feet, scoliosis, hip dysplasia behaviour problems, sleep disordered 
breathing, skin picking, dental problems, strabismus, hyperphagia and obesity (Prader, 
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Labhart et al. 1956, Cassidy and Driscoll 2009).  Classical facial features in PWS include 
narrow bi-frontal diameter, almond- shape eyes, narrow nasal bridge, and thin upper lip 
(Prader, Labhart et al. 1956, Cassidy and Driscoll 2009). 
During pregnancy mothers with previous normal pregnancies may notice delayed onset 
and intensity of foetal movements during pregnancy with a foetus that has PWS. It may 
raise the concern of the foetus having PWS and choriovillous sampling can be used for the 
genetic diagnosis of PWS. 
 
Figure 2: Human PWS gene (15q11) 
Panel A represents normal genotype. Black box represents normal imprinting of 15q11. 
 Panel B represents PWS genotypes. (P- paternal 15q11, M- maternal 15q11, PWS- 
Prader-Willi syndrome gene region, AS = Angelman syndrome gene region, IC = 
imprinting center, UPD = uniparental disomy, ID = imprinting center defect).  
 
(A) 
                                   
 
(B) 
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Figure 3: Charles Dickens depicted an obese boy who has somnolence in “The 
Posthumous Papers of Pickwick Club”. Similar to a child with PWS, obesity, somnolence, 
small hands and feet are easily recognizable in the drawing. 
 
 
At neonatal life the most striking features are hypotonia and poor feeding (Oiglane-Shlik, 
Zordania et al. 2006). The feeding problem can be due to hypotonia, poor suckling and 
swallowing. The neonate commonly needs gavage feeding for months. The other features 
suggestive of PWS are cryptorchism and small penis in males and hypoplastic labia in 
females (Stephenson 1980). Hypogonoadotrophic hypogonadism is thought to be 
responsible for the signs. In an early study it was described that in boys the scrotal skin is 
not completely flat despite of cryptorchism and in girls the hypoplasia of labia is only 
apparent on careful inspection (Stephenson 1980). 
The feeding problem usually resolves by 6 months of age and hyperphagia starts 
approximately from 18 months of age (Holm, Cassidy et al. 1993, Eiholzer 2005, 
Goldstone, Holland et al. 2008). Hypopigmentation is a common feature of PWS and it is 
reported to be present in about two thirds of the patients (Hittner, King et al. 1982, Butler 
1989). Chromosome 15 controls the activity of enzymes responsible for melanin 
production and it is reduced in PWS leading to hypopigmentation. Poor growth in early 
childhood is also a feature of PWS (Butler and Meaney 1987). In a study, adult patients 
with PWS underwent growth hormone provocation tests with Arginine and growth hormone 
releasing hormone and they were found to have growth hormone deficiency, which may be 
responsible for the poor growth (Grugni, Marzullo et al. 2006). Global developmental delay 
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is also seen in children with PWS. However, a study reported that PWS patients scored 
better on visual motor discrimination skills than auditory verbal processing skills (Curfs, 
Verhulst et al. 1991). Behaviour problems in PWS can be a major issue and common 
behaviour phenotypes are tantrums, skin picking, obsessiveness, stubbornness, stealing 
and violence (Holland, Whittington et al. 2003). Another disabling problem in PWS is 
sleep-disordered breathing (SDB) (Arens, Gozal et al. 1994, Livingston, Arens et al. 1995, 
Nixon and Brouillette 2002, Yee, Buchanan et al. 2007, Camfferman, Doug McEvoy et al. 
2008). SDB can be seen since early age but early oxygen therapy to infants with central 
hypo- ventilation and hypoxia appears to improve ventilation, central event index, and 
oxygenation (Urquhart, Gulliver et al. 2013). SDB leads to daytime hypersomnolence, 
respiratory failure and probable sudden death associated with growth hormone therapy 
(GHT) (Eiholzer, Nordmann et al. 2002, Craig, Cowell et al. 2006, Tauber, Diene et al. 
2008). GHT has been shown to be beneficial in children with PWS. Numerous studies 
described the benefits of GH therapy in this syndrome (Davies, Evans et al. 1998, Carrel, 
Myers et al. 2002, Hoybye, Hilding et al. 2003, Angulo, Castro-Magana et al. 2007, 
Hoybye 2007, Myers, Whitman et al. 2007, Lindgren and Lindberg 2008, Mogul, Lee et al. 
2008). GHT also improves the linear height and body composition in patients with PWS 
(Davies, Evans et al. 1998, Carrel, Myers et al. 1999, Davies 1999, Carrel, Myers et al. 
2002, Eiholzer, L'Allemand et al. 2004, Bertella, Mori et al. 2007, Myers, Whitman et al. 
2007, Lindgren and Lindberg 2008, de Lind van Wijngaarden, Siemensma et al. 2009). 
Children with PWS treated with GH (1 mg/m2/day) for 2 years demonstrated normalization 
of height standard deviation score, faster growth in head circumference, increased lean 
body mass accrual and decreased body fat together with improved language and cognitive 
functions (Myers, Whitman et al. 2007). In another study GH was continued for total of 4 
years in three cohorts receiving different doses of GH. The benefit on growth velocity, 
body composition (lean body mass) and resting energy expenditure was noted with higher 
doses of GH (7 mg/m2/wk and 10.5 mg/m2/wk) but not with 2.1mg/m2/wk dose (Carrel, 
Myers et al. 2002). Bone mineral density however improved in all studied doses of GH 
(Carrel, Myers et al. 2002). Moreover, GH improved sleep-related breathing disorders in 
children with PWS in a study in which 19 out of 25 patients had improvement in the 
Apnoea/ Hypopnoea Index (AHI) and Central Index (CI), but not of the Obstructive Index 
(OI) when polysomnography 6 months after commencement of GH was compared to that 
of baseline (Eiholzer, L'Allemand et al. 2004, Miller, Silverstein et al. 2006).  One study 
examined the effect of commencing GHT early in childhood by analyzing data from the 
Ozgrow database of Australia and New Zealand regarding children with PWS on GH 
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therapy. The Australasian Paediatric Endocrine Group (APEG) established the Ozgrow 
database in an attempt to collect data pertaining to GH therapy in children in Australia and 
New Zealand.  It was found that in children with PWS, there is better linear growth if GHT 
is started before three years of age than after three years (Nyunt, Harris et al. 2009). 
However, in a mortality review in patients with PWS, the majority of sudden death was 
related to respiratory pathology (Eiholzer, Nordmann et al. 2002, Tauber, Diene et al. 
2008) and this finding was also supported by a study of the KIGS, Pfizer international 
Growth Database (Craig, Cowell et al. 2006). 
Starting from 2008, the Commonwealth Government of Australia started to subsidize 
growth hormone therapy to all children who were genetically diagnosed of PWS until the 
age of 18 years. All children with PWS who are not severely obese (200% of ideal weight) 
receive growth hormone therapy (GorowthHormoneProgramme, DepartmentofHealth et al. 
2014). 
Patients with PWS have delayed onset of puberty in both males and females (Butler 1990, 
Eiholzer, Grieser et al. 2007). It is due to hypogonadotrophic hypogonadism. Sex steroids 
therapy not only induces pubertal changes but also improves bone mineral density (BMD) 
(Eiholzer, Grieser et al. 2007, Cassidy and Driscoll 2009). Central hypothyroidism is seen 
in 19% of patients with PWS (Sher, Bistritzer et al. 2002, Miller, Goldstone et al. 2008) and 
treatment with thyroxine is important for the neuronal, metabolic and bone health. One 
study reported very high prevalence of central hypoadrenalism in children with PWS using 
over-night Metyrapone test (de Lind van Wijngaarden, Otten et al. 2008). Subsequent 
studies, including our group from Brisbane, Australia, using low dose Synacthen test 
(Nyunt, Cotterill et al. 2010, Grugni, Beccaria et al. 2013), and a study using standard 
Synacthen test and insulin tolerance test (Farholt, Sode-Carlsen et al.), did not find such 
high prevalence of central hypoadrenalism in patients with PWS. Those studies prevented 
the use of physiological replacement or supra-physiological doses of corticosteroid during 
periods of stress. 
PWS patients, during neonatal life and infancy, have feeding problem and failure to thrive 
(Cassidy and Driscoll 2009). The underlying cause for the feeding problem is thought to be 
poor sucking and swallowing related to muscular hypotonia. As a result there is failure to 
thrive. However, at an older age the appetite changes to insatiable form. The age of 
change in appetite varies in the current literatures. Some reported onset of weight gain is 
from 15 months to 4 years (Holm and Pipes 1976), 1 to 6 years (Butler 1990) and 10 to 18 
months (Ehara, Ohno et al. 1993). After the change in appetite, the patients usually forage 
and often eat non-food items or discarded food. If they have free access to food, they do 
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not eat faster but longer than obese controls (Zipf and Berntson 1987, Lindgren, Barkeling 
et al. 2000). The fat mass is increased (up to 47%) compared to controls (Brambilla, Bosio 
et al. 1997, Goldstone, Brynes et al. 2002). The pathophysiology of the dimorphic nature 
of appetite and weight gain is unknown. It may be due to the differences in relation 
between ghrelin, acylated and des-acylated, and obestatin during young age and older 
age are responsible for dimorphic nature of appetite and weight gain. 
Obesity becomes a major problem in adolescence age and it is believed to be due to well- 
described hyperghrelinaemia (Holland, Treasure et al. 1993, Lindgren, Barkeling et al. 
2000, DelParigi, Tschop et al. 2002, Haqq, Farooqi et al. 2003, Butler and Bittel 2007). 
Although ghrelin stimulates appetite via Arcuate nucleus of the hypothalamus, the causal 
relation between ghrelin and hunger in PWS has not been established. The available 
evidence is higher blood ghrelin level is associated with higher subjective sense of hunger 
(DelParigi, Tschop et al. 2002). Reduced energy expenditure may also contribute to the 
development of obesity in PWS (van Mil, Westerterp et al. 2000, van Mil, Westerterp et al. 
2000, Butler, Theodoro et al. 2007). Two cross sectional studies identified that adults with 
PWS had a number of orthopaedic problems such as developmental dysplasia of hips, 
scoliosis, genu vulgum, and ankle abnormalities (West and Ballock 2004, Kroonen, 
Herman et al. 2006). Those conditions hinder patients with PWS to be physically active. 
Other features of PWS include high pain threshold, inability to vomit, abnormal 
temperature regulation and acute abdomen due to gastric dilatation and necrosis (Cassidy 
and Driscoll 2009). 
A number of studies examined the phenotypic difference in different genotypes of PWS. 
Patients with Type I deletion were found to have more behavioural and psychological 
problems than those with type II deletion or maternal UPD (Butler, Bittel et al. 2004). 
However, other studies did not find any difference in cognitive and behavioural phenotypes 
between two types of deletions (Milner, Craig et al. 2005, Varela, Kok et al. 2005). PWS 
patients with maternal UPD, are less likely to have typical facial features (Cassidy, 
Forsythe et al. 1997) and are more likely to have better verbal IQ (Roof, Stone et al. 2000).  
     
1.2: PWS and Hypothalamic dysfunction 
The hypothalamus is critical in regulating energy homeostasis by controlling hunger, 
satiation and energy expenditure in response to a variety of peripheral signals. Clinical 
features of PWS such as a combination of endocrine disorders; sleep- related breathing 
control disorder; defective temperature regulation; high pain threshold; inability to vomit; 
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hypotonia; developmental delay; hyperphagia; obesity and behavioural problems suggest 
that PWS may be due to defective Hypothalamus. Hypothalamus secretes releasing 
hormones which controls the production of pituitary hormones and deficiencies of such 
releasing hormones is believed to result in common endocrinological abnormalities of 
PWS. For example growth hormone secretions defect (Grugni, Marzullo et al. 2006), , 
central hypothyroidism (Sher, Bistritzer et al. 2002) are due to the deficiency of growth 
hormone releasing hormone, and thyrotrophic releasing hormone respectively. Previously 
hypogonadism was thought to be due to hypogonadotrophic hypogonadism (Stephenson 
1980) but recent reports suggest the primary gonadal failure is the major component of 
hypogonadism (Hirsch, Eldar-Geva et al. 2009, Eldar-Geva, Hirsch et al. 2010). Hirsch et 
al. reported that male patients with PWS had low to undetectable inhibin B, low 
testosterone and leutinising hormone. Eldar-Geva et al. reported that adult female PWS 
patients had low inhibin-B, low normal oestradiol and low leutinising hormone.    
Sleep- disordered breathing (SDB) in PWS includes hypoventilation, reduced ventilatory 
response to hypoxia and hypercapnia, sleep- related hypoxaemia and obstructive sleep 
apnoea (OSA) (Nixon and Brouillette 2002). Apart from OSA, which may be related to 
obesity, the other SDB in PWS indicate hypothalamic regulatory defects.  There are other 
abnormalities of sleep and arousal in PWS such as reduced rapid eye movement (REM) 
latency, sleep onset REM periods and cataplexy independent of obesity (Vela-Bueno, 
Kales et al. 1984, Kaplan, Fredrickson et al. 1991, Manni, Politini et al. 2001). Abnormal 
REM sleep indicates that the orexin control defect at hypothalamic level (Nevsimalova, 
Vankova et al. 2005). Furthermore, high pain threshold, inability to vomit and hyperthermia 
(Cassidy and Driscoll 2009) seen in PWS suggest abnormal hypothalamus.  
 
1.3: Abnormal hypothalamus imaging in PWS 
 There are a number of studies using functional imaging that related PWS to a 
hypothalamic disorder (Shapira, Lessig et al. 2005, Hinton, Holland et al. 2006, Holsen, 
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Zarcone et al. 2006, Dimitropoulos and Schultz 2008). In a functional Magnetic Resonance 
Imaging study, with the stimulus of high calorie diet, there was increased neuronal 
activation of appetite and motivation centers such as hypothalamus and Occipito- Frontal 
cortex in individuals with PWS than controls (Dimitropoulos and Schultz 2008). In an 
another study using functional MRI on obese adult PWS patients, the lag time between 
oral glucose intake and activation of satiety centers of hypothalamus and other areas of 
brain is longer than that of obese controls (Shapira, Lessig et al. 2005). Measuring 
regional cerebral blood flow using positron emission tomography, PWS patients were also 
found to have absent pattern of neural activation associated with satiety even after a 
higher energy load but similar neural representation of hunger after overnight fasting 
(Hinton, Holland et al. 2006).  
In another study using functional MRI, the PWS individuals had higher food-item-induced 
activity in limbic reward areas and lower activity at hypothalamus and hippocampus before 
a meal (Holsen, Savage et al. 2012).  After a test meal, PWS individuals had higher 
activity in hypothalamus, amygdala and hippocampus but lower inhibitory activity in higher 
cortical regions. The authors concluded with the proof of functional MRI results that in 
PWS there is increased food reward and lack of cortical control of satiety.  Hornea et al 
studied the grey and white matter volume, and their distributions in the brain in PWS 
comparing against healthy weight non-PWS controls (Honea, Holsen et al. 2012). Using a 
custom voxel-based morphometry processing stream, the authors showed PWS 
individuals had lower grey matter volumes in pre-frontal, orbitofrontal and temporal 
cortices, hippocampus and parahippocampal gyrus, and lower white matter volumes in the 
brain stem, cerebellum, medial temporal, and frontal cortex. Within PWS group, individuals 
with paternal deletion had lower grey matter volume primarily in the prefrontal and 
temporal cortices, and lower white matter in the parietal cortex. Those with maternal uni-
parental disomy had more extensive lower gray and white matter volumes in the 
orbitofrontal and limbic cortices compared to the control group. This may be the 
preliminary findings to explain the difference in the behavior phenotypes in different 
genetic subgroups of PWS.  
 
1.4: Genetic explanation of hypothalamic dysfunction in PWS 
 Mage Like-2 (Magel 2) gene falls within PWS region, which is expressed mainly through 
paternal- specific allele, and its main function is to control the circadian rhythm by the 
hypothalamus. Magel- 2 is highly expressed in Supra- chiasmatic nucleus, which is 
responsible for circadian rhythm through orexin signaling system (Peyron, Tighe et al. 
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1998, Sakurai, Amemiya et al. 1998). Mice deficient in Magel-2 were found to have orexin 
signaling defect and therefore have abnormal circadian rhythm and reduced physical 
activity (Kozlov, Bogenpohl et al. 2007). Moreover, Magel 2 knockout mice show many 
features of PWS such as growth failure, hypogonadotropic- hypogonadism, and skin 
picking (Bischof, Stewart et al. 2007). Magel-2 null female mice displayed delayed and 
lengthened puberty while male mice had low testosterone and low gonadotropins. Both 
genders showed early reproductive decline and infertility (Mercer and Wevrick 2009). 
Necdin null mice have reduction in leutinising hormone releasing hormone and oxytocin 
neurones in hypothalamus as well as skin picking and improved visual memory similar to 
human PWS (Muscatelli, Abrous et al. 2000). Interestingly non- coding RNA, Snord116, in 
the PWS region was found to have expressions in para- ventricular and ventro- medial 
hypothalamus and arcuate nucleus (Zhang, Bouma et al. 2012). Two animal studies 
reported that paternally- derived Snord116 deleted mice had PWS phenotypes (Skryabin, 
Gubar et al. 2007, Ding, Li et al. 2008), and a case report claimed that deleted non- coding 
RNAs were responsible for all clinical features of PWS (Sahoo, del Gaudio et al. 2008). 
Those evidence supports that the underlying defect in PWS is at hypothalamus. Swabb et 
al. reported reduced number of oxytocin producing neurons in paraventricular nuclei in 
autopsy samples of PWS patients also suggested hypothalamic dysfunction (Swaab, 
Purba et al. 1995). 
 
1.5: Hypothalamic control of Autonomic Nervous System (ANS) 
ANS consists of parasympathetic (PSNS) and sympathetic nervous systems (SNS). It’s 
important function is to maintain homeostasis. The main neurons involved in ANS are 
preganglionic and postganglionic neurons. For SNS, preganglionic neurons are seen in 
intermediolateral cell column in the thoracic and lumbar (T1 to L2) segments of the spinal 
cord and ends at the paravertebral chain ganglia. Postganglionic neurons then commence 
from the ganglia and traverse a long path to end in the target organs such as heart, 
muscle vasoconstrictor, visceral vasoconstrictor, skin vasoconstrictor, skin vasodilator, 
sudomotor, pilomotor, pupilomotor, viseromotor units (Janig and Habler 2003, Guyenet 
2006). 
Parasympathetic outflow originates from the brain stem and sacral spinal cord. Unlike 
SNS, its ganglions are within or very close to its target organs. For example, the vagus 
nerve carries parasympathetic signals from medulla to target organs. Sacral component of 
parasympathetic output originates from lateral grey matter at S2 to S4 segments of sacral 
spinal cord (Birder, de Groat et al. 2010). 
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The central regulation mechanism of ANS involves the limbic system, which includes 
hypothalamus, certain brain stem regions particularly nucleus tractus solitarius and the 
spinal cord. Because of its important and extensive regulatory function, the hypothalamus 
is known as the main or head ganglion of the ANS. A study using a neuronal tracer 
cholera toxin B indicated that parasympathetic and sympathetic projection neurons 
intermingle in paraventricular nucleus (PVN) of hypothalamus and thus it controls both 
arms of ANS (Naito, Ohmori et al. 1994). Activation of different regions of the 
hypothalamus produces a variety of coordinated autonomic responses. For example, 
activation of dorsal hypothalamus increases the blood pressure, intestinal motility, and 
intestinal blood supply but decreases the blood supply to the skeletal muscles. However, 
activation of ventral hypothalamus increases in blood pressure and blood supply to the 
skeletal muscles but decreases intestinal motility and blood supply to the intestines 
(Thomas 2011). 
Hypothalamus integrates afferent signals and discharges efferent output to target organs. 
For example, it receives afferent signals from the limbic system, which is responsible for 
emotion, and activates the efferent sympathetic nervous system which represents the 
classical “fight or flight” response described by Walter Cannon in 1929. Moreover, 
amygdala, hippocampus and prefrontal cortex receive associational information from the 
cortical and subcortical areas that are involved in higher sensory processing and memory. 
The output from these involves activation of ANS and hypothalamo-pituitary-adrenal axis 
(HPA) (Herman, Figueiredo et al. 2003).  
Regulation of the circadian rhythm, sleep- wake cycle, thermoregulation, glucoregulation, 
osmoregulation, response to stress, and immunoregulation are controlled by 
hypothalamus and pre- optic area (Saper 2002, Thompson and Swanson 2003). The pre-
optic area is functionally divided into three functional zones: periventricular, medial and 
lateral zones (Thompson and Swanson 2003). The periventricular zone includes supra- 
chiasmic nucleus that controls circadian rhythm and pituitary gland. Medial pre- optic area 
orchestrates and coordinates autonomic and endocrine output for thermoregulation, 
osmoregulation and stress response (Sawchenko, Li et al. 2000, Yoshida, Li et al. 2009). 
The paraventricular nucleus, dorso- medial hypothalamus and lateral hypothalamic area 
are main regions for ANS output (Saper 2002).  
The brain stem acts as the relay station and also regulates ANS. Peri- aqueductal gray 
matter, para- brachial nucleus, some areas of pons and medulla including nucleus tractus 
soliterius and medullary raphe receive converging visceral and somatic information; 
reciprocally interconnect with the hypothalamus and spinal tracts; and generate stimulus- 
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specific patterns of autonomic, endocrine and motor responses (Cersosimo and Benarroch 
2013). Medulla oblongata and Pons are crucial for tonic and reflex regulation of arterial 
pressure via the spinal sympathetic outflow (Alexander 1946, Dampney 1981). The 
neurons in the nucleus tractus solitarius are where afferent signals from baro- receptors 
terminate (Reis, Granata et al. 1984). Those neurons maintain tonic background drive to 
sympathetic preganglionic neurons directly (Dampney 1981, Reis, Granata et al. 1984); 
and are the target organs for the centrally acting anti- hypertensive agents such as 
Clonidine (Haeusler 1973). A1 fibers from the Nucleus Tractus Solitarius project 
cephalically to the paraventricular and supraoptic nuclei of hypothalamus for integration of 
sensory signals (Blessing, Goodchild et al. 1981, Blessing, Jaeger et al. 1982). On the 
other hand, C1 fibers of the NTS projects caudally to the spinal cord (Ross, Ruggiero et al. 
1984). The intermediolateral column of the spinal cord innervates adrenal medulla and 
sympathetic ganglia (Reis, Granata et al. 1984).The gamma amino- butyric acid (GABA) is 
the main neurotransmitter for the NTS- C1 projection (Yamada, Norman et al. 1982).  
The vagus nerve means wandering in Latin and is the longest cranial nerve. It arises from 
medulla and traverses a long path from the cranium to the neck, thorax, and abdomen 
(Ruffoli, Giorgi et al. 2011). It is formed from the 4th branchial branch and comprises mostly 
sensory fibers carrying visceral signals from head, neck and thorax (Agostoni, Chinnock et 
al. 1957). The primary sensory input of vagus nerve is mostly from baro- receptors and 
chemoreceptors from the heart and aortic arch. Those afferent fibers terminate at the NTS 
which further co- ordinates sympathetic and parasympathetic discharges (Nieuwenhuys, 
Voogd et al. 2008). A short pathway connects NTS to dorsal motor nucleus of vagus in 
discharging parasympathetic output (Nieuwenhuys, Voogd et al. 2008). The fibers arising 
from dorsal motor nucleus of vagus descend and terminate in parasympathetic ganglia 
which are in close proximity to the target organs (Jean 1991, Travagli, Hermann et al. 
2006). Different parts of dorso- motor nucleus of vagus have parallel stimulatory and 
inhibitory pathways on gastrointestinal motility (Chang, Mashimo, & Goyal, 2003). Most of 
the inhibition induced by NTS- dorsal motor nucleus of vagus is mediated by GABA acting 
on the GABA-A receptor (Travagli, Gillis et al. 1991). Conversely, the excitatory action is 
mediated by glutamate on N- methyl D- aspartate (NMDA) receptors and non- NMDA 
receptors (Willis, Mihalevich et al. 1996).Tonic fashion of GABAergic output from NTS to 
dorsal motor nucleus of vagus has an impact on vagal reflex control of its target organs 
(Travagli, Hermann et al. 2006). (Figure 4) 
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Figure 4: ANS reflex Arc and its connections to hypothalamus via nucleus tractus 
solitaries. IX- Glossopharyngeal nerve, X- Vagus nerve, C1- C1 fibers of medulla 
oblongata, DMV- dorsal motor nucleus of vagus nerve, GABA- glutamic acid 
dehydrogenase 
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1.6: Hypothalamus and ANS in PWS 
Since PWS is considered to be a hypothalamic dysfunction, the control of ANS in PWS is 
likely to be defective. There is one case- control study that reported that there is a 
detectable ANS dysfunction in patients with PWS (DiMario, Dunham et al. 1994). In the 
study participants had measurements of simultaneous and serial electrocardiogram 
(ECG), pulse rate and blood pressure during lying and standing and plasma 
norepinephrine during lying and standing. The pupillary response to topical Pilocarpine 
(pupillary constrictor acting on muscarinic receptors of parasympathetic nervous system) 
was also examined to complement the cardio- vascular response to physiological 
stimulation of ANS. In PWS cohort, there was less pronounced change in diastolic blood 
pressure after standing, and higher pulse rate in those with greater BMI. PWS participants 
had trend towards lower diastolic blood pressure. Pupillary constriction of 2 mm or more 
with topical Pilocarpine is noted in half of the PWS cohort but not in the controls, and the 
30:15 R-R interval ratio on the ECG was abnormal in 6 out of 14 PWS participants. The 
authors concluded that there was detectable dysfunction of ANS in PWS patients 
particularly in diminished parasympathetic activity. When dissecting further on the results 
of this study, poor homeostatic regulation of diastolic blood pressure on standing in PWS 
cohort suggested sympathetic failure to vasoconstrict when the blood column dropped 
because of gravity and baro- receptors were stimulated. Pilocarpine is a 
parasympathomimetic and in normal individuals with intact muscarinic receptors on 
pupillary smooth muscles, it constricts pupils. In the study, none of the control participants 
had pupillary constriction but 50% of the PWS group did. It indicated that the muscarinic 
receptors in normal controls were not responsive but only 50% of PWS group were to 
Pilocarpine. The effect of Pilocarpine did not indicate any central ANS actions. DiMario et 
al also reported in a case- control study that PWS patients had lower average temperature 
and lower temperature trend suggesting poor sympathetic function (DiMario and Burleson 
2002). The same group of authors further examined the parasympathetic function by 
respiratory sinus arrhythmia and found that the PWS group had less variable heart rate 
with different phases of breathing indicating poor parasympathetic outflow (DiMario, Bauer 
et al. 1993).  
Purtell et al also studied ANS function in PWS. In the study Purtell et al used SphygmoCor 
(AtCor Medical, Sydney, NSW, Australia) to measure heart rate variability and arterial 
stiffness in adults with PWS and healthy obese controls (Purtell, Jenkins et al. 2013). The 
participants were then given a mixed meal to stimulate ANS function and the 
measurements were done before the meal and at 30, 60, 120, 180 and 240 minutes after 
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the meal. The PWS group displayed similar high frequency heart rate variability after a 
meal to the control group suggesting parasympathetic function is not different to the 
controls after a meal. The low frequency responsiveness, which is dependent upon both 
sympathetic and para- sympathetic functions, was reduced in PWS group.  
Wade et al. also examined the cardiac autonomic modulation in a case- control study and 
baro- reflex sensitivity (Wade, De Meersman et al. 2000). In the study, electrocardiogram, 
blood pressure, heart rate and respiration were recorded in supine, after transition from 
supine to standing, sitting, during a Valsava maneuver, while performing moderate 
exercise, and during recovery from exercise in sitting position. The study did not find any 
difference in cardiac autonomic modulation (Wade, De Meersman et al. 2000).  The above 
studies examined a single target organ, the heart, which has dual ANS innervations. The 
activation and inhibition of both sympathetic and para- sympathetic systems on heart occur 
quickly and frequently at times; and slowly and in sustained fashion at another times (Saul, 
Albrecht et al. 1988, Thomas 2011). For this reason it may be very difficult to study the 
ANS function on a single organ at a single time point. 
The higher pain threshold that is commonly seen in PWS may be attributed by diminished 
ANS action on cutaneous nerve complexes and pain receptors via GABA system 
(Hoefnagel, Costello et al. 1967, Bray, Dahms et al. 1983). Selective activation of GABA-B 
receptor by baclofen produced anti-nociception, that is increased pain threshold (Hill and 
Bowery 1981, Sawynok and Dickson 1983). Reduced salivation also suggests paucity of 
parasympathetic nervous outflow in PWS (Hoefnagel, Costello et al. 1967). PWS patients 
have abnormal temperature regulation and it may be due to defective regulation of ANS 
(Bray, Dahms et al. 1983).  
 
1.7: Ghrelin 
Ghrelin has growth hormone releasing activity as it is thought to be an endogenous ligand 
of the growth hormone secretagogue receptor (Kojima, Hosoda et al. 1999). Ghrelin is a 
peptide of 28 amino acids secreted from the fundus of the stomach. N- octanoylation by 
the enzyme ghrelin O-acyl transferase (GOAT) (Gutierrez, Solenberg et al. 2008, Yang, 
Brown et al. 2008) at serine- 3 residue of ghrelin molecule to form acylated ghrelin which is 
an active form of ghrelin (Kojima, Hosoda et al. 1999). In human, the prominent form of 
circulating ghrelin is des- acyl form (2.5 folds higher than acyl ghrelin) (Broglio, Gottero et 
al. 2004) and it was initially considered to be an inactive form of ghrelin (Hosoda, Kojima et 
al. 2003). Active ghrelin acts on the G- coupled receptors with specific ligand which are 
present largely in pituitary and hypothalamus (Gnanapavan, Kola et al. 2002). The 
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receptors are also seen in other parts of the brain which are involved in control of bio-
rhythms, mood, cognition, memory and learning (van der Lely, Tschop et al. 2004). In 
addition, they are also reported to be present on multiple organs such as intestine, 
kidneys, heart, adrenal glands, pancreas, thyroid and gonads (Gnanapavan, Kola et al. 
2002). 
Ghrelin molecule derives from prohormone preproghrelin which consists of 117 amino 
acids. Other peptides called obestatin and desacyl ghrelin also derives from preproghrelin 
(Kojima, Hosoda et al. 1999, Delhanty, Neggers et al. 2012). While ghrelin is orexigenic, 
obestatin is anorexigenic although both peptides derive from the same parent molecule. 
Rats treated with obestatin had reduced appetite, weight and jejunal motility (Zhang, Ren 
et al. 2005).  
At Arcuate nucleus of hypothalamus ghrelin increases expression of neuropeptide Y (NPY) 
and Argouti Related Peptide (ArgRP) which increase short- term and sustained appetite 
respectively (Nakazato, Murakami et al. 2001). Desacyl ghrelin was previously thought to 
be an inactive peptide (Hosoda, Kojima et al. 2003) but current understanding suggests 
the opposite (Delhanty, Neggers et al. 2012). It is believed to be an independent hormone 
and it rapidly modulates the expression of metabolically important genes in adipose tissue, 
muscles and liver (Delhanty, Sun et al. 2010). Desacyl ghrelin also acts on growth 
hormone secretagogue receptor and only in supra physiological concentration it displaces 
acyl ghrelin (Gauna, van de Zande et al. 2007). The antagonistic action against acyl 
ghrelin was supported by another study (Broglio, Gottero et al. 2004). In the study co- 
administration of acyl and desacyl ghrelin abolished acyl ghrelin- induced change in 
plasma insulin and glucose. Increased acyl and desacyl ghrelin ratio is associated with 
obesity and type 2 diabetes mellitus (Barazzoni, Zanetti et al. 2007, St-Pierre, Karelis et al. 
2007). Plasma insulin and HOMA-IR were negatively correlated with desacyl ghrelin but 
positively with acyl ghrelin and acyl to desacyl ghrelin ratio (Barazzoni, Zanetti et al. 2007). 
Vagus nerve is thought to be important in controlling ghrelin secretion. Vagus nerve 
experts tonic suppression of ghrelin production as higher blood ghrelin level was found in 
vagotomised mice (Lee, Wang et al. 2002). Furthermore, in an animal study the plasma 
ghrelin level was suppressed after electrical stimulation on the vagus nerve (Murakami, 
Hayashida et al. 2002). Increased ghrelin level is seen during fasting when the vagal 
action is at a nadir. 
Physiologically there is pre-prandial rise and postprandial fall of ghrelin associated with a 
meal (Cummings, Purnell et al. 2001). The pre-prandial rise of the level is thought to be 
due to the cephalic phase of the digestive process, modulated by the efferent vagus nerve. 
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The rise of plasma ghrelin during fasting was less pronounced in vagotomised rats 
compared to sham operated controls before feeding (Williams, Grill et al. 2003). In human 
studies cephalic phase stimulation of food via vagal efferent fibers by sham feeding was 
found to be associated with rise in ghrelin before meal and with more rapid fall in 
postprandial period (Robertson, Jackson et al. 2001, Arosio, Ronchi et al. 2004, Bizzarri, 
Rigamonti et al. 2004, Heath, Jones et al. 2004). In healthy human subjects, the plasma 
ghrelin level was significantly lower after a sham feeding (chew and spit) than that of those 
who had a standard mixed meal (Arosio, Ronchi et al. 2004). Sham feeding has been 
proven to be an inducer for parasympathetic nervous outflow (Robertson, Jackson et al. 
2001). 
The physiological post- prandial fall is believed to be due to vago-vagal inhibition 
(Robertson, Jackson et al. 2001, Arosio, Ronchi et al. 2004, Bizzarri, Rigamonti et al. 
2004, Heath, Jones et al. 2004). From those literatures it has been postulated that 
parasympathetic nervous system suppresses blood ghrelin level tonically and at 
postprandial period.  
 
1.8: Nesfatin-1 
First information of Nucleobindin 2 (NUCB2) - encoded satiety and fat- influencing protein 
1 (nesfatin-1) was provided in 2006 (Oh, Shimizu et al. 2006). It inhibits food intake upon 
injection to ventricles in animal studies (Oh, Shimizu et al. 2006, Shimizu, Oh et al. 2009, 
Purtell, Jenkins et al. 2013). Only the Mid- segment of nesfatin-1 contains more potent 
anorexigenic effect compared to N- segment or C- segment of Nesfatin-1 (Shimizu, Oh et 
al. 2009).  The anorexigenic effect of mid- segment of nesfatin-1 is independent of leptin 
pathway as reduced food intake was still observed in db/db mice and overfed obese mice 
(Shimizu, Oh et al. 2009, Purtell, Jenkins et al. 2013). Central injection of nesfatin-1 
increases c-fos expression in Paraventricular nucleus of hypothalamus and Nucleus 
Tractus Solitarius (Young, Deo et al. 2010, Purtell, Jenkins et al. 2013). It indicated that 
Nesfatin-1 acts on hypothalamus and NTS. 
In another animal study using immunohistochemistry, co-localization of ghrelin and 
nesfatin-1 was observed in both hypothalamus and anterior intestine of the goldfish 
(Young, Deo et al. 2010). In the same study, intracerebroventricular injection of nesfatin-1 
and ghrelin reduced the mRNA expression of pre-proghrelin and NUCB2 in hypothalamus 
respectively indicating reverse relationship between ghrelin and Nesfatin-1 (Young, Deo et 
al. 2010).  
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Maejima et al. elegantly described that nesfatin-1 regulates oxytocinergic signaling in 
hypothalamus and Nucleus Tractus Solitaries which in turn stimulates melaocortin 
pathway to induce anorexia independent of leptin (Purtell, Jenkins et al. 2013).  
To date, little is known about plasma profile of nesfatin-1 in relation to a meal in healthy 
human or nesfatin-1 status in PWS where satiety is not commonly achieved after a meal. 
 
 1.9: PWS and hyperghrelinaemia 
In PWS, energy gain is increased by hyperphagia and the satiation cannot be effectively 
achieved after food intake (Holland, Treasure et al. 1993). In the case-control study 
hyperphagia in PWS was clearly demonstrated by using cucumber sandwiches. High 
Ghrelin level is found in PWS and it is believed to be responsible for hyperphagia and poor 
satiation in PWS (DelParigi, Tschop et al. 2002, Haqq, Stadler et al. 2003, Haqq, 
Grambow et al. 2008). Higher fasting plasma ghrelin level and denser ghrelin secreting 
cells in stomach were seen in PWS than control group (Haqq, Farooqi et al. 2003, Choe, 
Song et al. 2005, Haqq, Grambow et al. 2008). However, the direct link between high 
ghrelin level and increased appetite has not been established to this stage. DelParigi et al. 
reported that there was positive correlation between plasma ghrelin level and subjective 
ratings of hunger (DelParigi, Tschop et al. 2002).    
A number of studies reported failure of suppression of plasma Ghrelin after a meal but 
an uncontrolled study demonstrated lower plasma Ghrelin after a meal than before a meal 
in patients with PWS (DelParigi, Tschop et al. 2002, Haqq, Stadler et al. 2003, Paik, Choe 
et al. 2006, Gimenez-Palop, Gimenez-Perez et al. 2007).   
Therefore hyperphagia in PWS may be due to high and unregulated ghrelin secretion, 
which may be due directly to low, or loss of tonic vagal suppression, and lack of post-
prandial vago-vagal suppression of ghrelin respectively.  Alternatively it may also be 
indirectly due to low nesfatin-1 as a result of dysfunctional ANS in PWS. 
 
1.10: Hypothalamic control of energy homeostasis 
Arcuate nucleus (ARC) of hypothalamus integrates information conveyed by different 
peripheral signals of energy homeostasis.  It produces Neuropeptide Y (NPY) and agouti- 
related protein (Agrp) which are orexigenic peptides. These neuropeptides are associated 
with central control of appetite as their expression increase at the time of maximal 
spontaneous feeding in an animal study. NPY is a 36 amino acids peptide similar to 
pancreatic polypeptide family (Tatemoto, Carlquist et al. 1982). In an animal study, 
injection of NPY into cerebral ventricles leads to increased food intake (Clark, Kalra et al. 
35 
 
1984, Stanley and Leibowitz 1984, Stanley and Leibowitz 1985). NPY stimulates Argp, 
which increases sustained food intake (Hagan, Rushing et al. 2000). Another animal study 
showed that when rats were treated with intracerebroventricular injections of ghrelin, NPY 
and Argp there was significant reduction in locomotor activity of the animals compared to 
the controls that received vehicle (Tang-Christensen, Vrang et al. 2004). As animals do not 
have volitional exercise, the reduction in locomotor activity can be considered as non- 
exercise associated thermogenesis. 
Lateral hypothalamus contributes to food intake via orexin and melanin- concentrating 
hormone (MCH) although the stimulating effect of food intake in this pathway is short lived 
(Sakurai, Amemiya et al. 1998). Orexin cells sends projections to ARC and they form 
synapses with NPY and Argp cells which in turn synapse back to orexin cells (Horvath, 
Diano et al. 1999). There are two groups of orexin neuropeptide, orexin A and orexin B 
(Willie, Chemelli et al. 2001). The peptides act on orphan G- coupled- receptor protein 
(Sakurai, Amemiya et al. 1998). Orexin secreting neurones are seen in lateral 
hypothalamic and perifonical area (Peyron, Tighe et al. 1998, Sakurai, Amemiya et al. 
1998, Chemelli, Willie et al. 1999). Its neurones are projected throughout central nervous 
system to nuclei that control feeding (Kotz 2006), sleep- wakefulness, neuroendocrine 
functions and autonomic regulation (van den Top, Nolan et al. 2003). Orexin knockout 
mice showed sleep- onset Rapid Eye Movement (REM) period, sleep fragmentation and 
reduced wakefulness compared to wild littermates (Hara, Beuckmann et al. 2001). 
Targeted disruption of orexin gene in mice resulted in phenotype similar to human and 
canine narcolepsy (Willie, Chemelli et al. 2001). The sleep- related breathing disorders in 
PWS are also similar to orexin deficiency and it is postulated that PWS is a state of orexin 
deficiency as part of hypothalamic lesion (Nevsimalova, Vankova et al. 2005). In a rat 
study, intra- cerebroventricular injection of orexin was associated with wakefulness and 
increased locomotor activity (Kiwaki, Kotz et al. 2004). 
ARC also has anorexigenic function through neurons that produce α- melanocyte 
stimulating hormone (α-MSH), which derives from cleaving of pro-opiomelanocortin 
(POMC) protein (Cone, Cowley et al. 2001). It binds the melanocortin receptors 3 and 4 
(MC3R/ MC4R) to reduce food intake (Boston, Blaydon et al. 1997). Moreover, POMC 
cells synthesize another anorexigenic peptide called cocaine and amphetamine related 
transcript (Elias, Lee et al. 2001). Insulin, pancreatic hormone, and leptin, an adipokine, 
increases α-MSH and decreases NPY and Argp activities in ARC of the hypothalamus 
resulting in reduced food intake and increased energy expenditure. 
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There is a number of gastro- intestinal and other meal related hormones or peptides that 
act on the hypothalamus via vagus nerve or cervical sympathetic nerves. They include 
cholecystokinin, glucagon- like peptide 1, insulin, pancreatic peptide Y, apolipoprotein A-
IV, enterostatin, bombesin, oxyntomodulin, and amylin which are considered to be 
satiation signals.  
 Adiposity signal, leptin, on the other hand acts on POMC and MC 3/4R system at ARC 
increases energy expenditure. Leptin deficient ob/ob mice had increased oxygen 
consumption after treatment with leptin (Pelleymounter, Cullen et al. 1995). The ob/ob 
mice have lower energy expenditure than their control littermates suggesting leptin is 
important for energy expenditure (James, Davies et al. 1978). Insulin is another adiposity 
signal and when injected into paraventricular nuclei (PVN) of hypothalamus, it increased 
energy expenditure without increasing locomotor activity (Menendez and Atrens 1991). 
Similarly, microinjection of CART to ARC resulted in increased locomotion(Abbott, Rossi et 
al. 2001). In an animal study, mice with mutation of MC4R showed reduced locomotor 
activity and oxygen consumption compared to the wild type mice (Ste Marie, Miura et al. 
2000). PVN also mediates locomotor activity and energy expenditure by modulating 
sympathetic nervous outflow (Atrens and Menendez 1993). Thyrotropin releasing hormone 
produced by the hypothalamus also contributes to energy expenditure by stimulating 
thyroid stimulating hormone and thyroid hormone (Yarbrough 1979, Lechan and Fekete 
2006).  
After integration of the afferent peripheral signals in many parts of hypothalamus, efferent 
effector homeostatic mechanism ensues which include arousal, vigilance, physical activity, 
interaction with motor and autonomic nervous systems (Jones 2003).  
 
1.11: Energy Expenditure (EE) 
Total energy expenditure (TEE) can be generally divided in Basal Metabolic Rate, Activity 
related thermogenesis, energy cost of activity (AAT), and Thermic effect of food (TEF). 
Because thermic effect of food intake is negligible, energy expenditure is dependent upon 
Basal Metabolic rate and Activity thermogenesis (Levine 2004, Levine 2004). Basal 
metabolic rate (BMR) is the energy required for core body function and is measured at rest 
without food (Daan, Masman et al. 1989). Resting energy expenditure (REE) is defined as 
daily energy used during resting. BMR or REE usually accounts for approximately 60% of 
the daily energy expenditure (Ford 1984). Thermic effect of food is the energy used in 
digestion, absorption and storage of nutrients (Hill, DiGirolamo et al. 1985, Donahoo, 
Levine et al. 2004). It usually accounts for 10% of total energy usage.  Levine further 
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divides activity related thermogenesis into exercise- associated (EAT) and non- exercise 
associated thermogenesis (NEAT) that he defines as energy expenditure related to activity 
other than volitional exercise (Levine, Schleusner et al. 2000). NEAT includes fidgeting, 
chewing gum, pacing around a room, toe tapping, shopping, dancing, gardening and so 
on.  In industrialized countries the non- exercise associated thermogenesis is the most 
important component of total daily energy expenditure. Even in avid exercisers, non- 
exercise associated thermogenesis is the most predominant component of total daily 
energy expenditure. Low non- exercise associated thermogenesis due to mechanization of 
day to day life can lead to obesity (Levine 2007). 
 
1.12: EE in PWS 
In patients with PWS, unadjusted total energy expenditure, resting metabolic rate,  and 
activity associated thermogenesis were found to be low in a study (Butler, Theodoro et al. 
2007). Total energy expenditure and resting metabolic rate after correcting for fat mass 
remained significantly different. The authors related low metabolic rate to reduced lean 
body mass. However, the duration of the study was only 8 hours on each participant and 
the result may not represent the actual EE and EE was adjusted to neither weight nor fat 
free mass. Other studies found that resting and basal metabolic rates in patients with PWS 
are higher than the controls after having adjusted for the lean body mass (van Mil, 
Westerterp et al. 2000, Goldstone, Brynes et al. 2002). Obesity and relatively higher RMR 
suggests that the activity associated energy expenditure must be definitely low in patients 
with PWS. EAT may be insignificant because patients with PWS rarely exercise (Davies 
and Joughin 1993, van den Berg-Emons, Festen et al. 2008). Therefore NEAT represents 
AAEE in PWS and it is very likely to be low. ANS dysfunction and probably 
hyperghrelinaemia may be the causes of low NEAT in PWS.  
 
1.13: Measuring EE 
Measuring metabolic rates in children with PWS is made difficult by behaviour problems 
and current available methods of measuring metabolic rate may not be suitable as they 
can be cumbersome, intimidating and may cause claustrophobia. There is another device 
called Fitmate Pro that measures oxygen consumption in expired air to calculate metabolic 
rates. It is small, portable and less intimidating. Fitmate Pro has a facial mask that covers 
mouth and nostrils, which makes it a suitable alternative for measurement of metabolic 
rates and has been validated for the use for adults (Nieman, Austin et al. 2006, Nieman, 
Lasasso et al. 2007) but not for children.  
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Accelerometer is a device that is used to measure frequency and intensity of movement of 
human body. It is a uniaxial accelerometer that measures acceleration in vertical plane 
and calculates activity associated metabolic rate from the measurements. Actiheart is an 
accelerometer that measures uni- directional movement and heart rate to calculate 
metabolic rates. It is the first device that combines a heart rate monitor and accelerometer 
in a single unit. The main component of it is 6 mm thick with a diameter of 33 mm and 
houses a movement sensor, a rechargeable battery, a memory chip and other electronics. 
A wire approximately 100 mm in length runs to a smaller electronic chip. The total weight 
is only 10 gm. It measures heart rate variability and ECG amplitude for a set time 
resolution. It does the measurements in epochs, which is 15s, 30s and 1 min. The memory 
capacity of 128 kb allows the data to be stored for more than 11 days with an epoch 
setting of 1 minute.  
Acceleration is measured by piezoelectric element contained in the Actiheart with a 
frequency range of 1-7 Hz. This movement sensor generates a transient charge when 
exposed to acceleration and produces a voltage signal which in turn gets converted into a 
binary signal by 8 bit analog to digital converter. This results in 256 distinctive levels of 
acceleration (128 positive and 128 negative levels). Acceleration is quantified as a 
numerical difference from zero acceleration in binary units. The binary units are stored and 
summed up over the epoch. The sensitivity of Actiheart in measuring heart rates is 0.250 
mV. At the end of an epoch, mean R-R intervals of ECG is calculated and is converted to 
beats per minute.  
 
1.14: Reasons for performing this study 
Sinnema et al. in 2012 reported that the average life expectancy of individuals with PWS 
has increased over the recent years. In a cross sectional study published in 2011 by 
Sinnema et al., it was reported that individuals with PWS who are older than 50 years of 
age had cardiovascular disorders such as type 2 diabetes mellitus (50%), hypertension 
(25%), and stroke (25%) (Sinnema, Maaskant et al. 2011, Sinnema, Schrander-Stumpel et 
al. 2012). The authors reported early day-to-day functional decline in older PWS patients 
but not on the prevalence of ischaemic heart disease. Another study on PWS patients with 
mean age of 28 years showed they had higher high- sensitivity C- reactive protein, less 
exercise capacity, and greater microvascular dysfunction, that are associated with 
coronary artery disease (Patel, Harmer et al. 2007). In an adult PWS study, both visceral 
and subcutaneous adipose tissue increased with increasing age (Tanaka, Abe et al. 
2013). The adiposity was low among adult PWS patients while continuing growth hormone 
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therapy, but it increased with age to similar levels to untreated patients once growth 
hormone was ceased (Tanaka, Abe et al. 2013). In obese subgroup of adult PWS patients, 
adiponectin, which is cardio- protective (Bluher and Mantzoros 2015), was low as visceral 
adiposity increased, and was negatively correlated with total cholesterol, low- density 
lipoprotein and triglyceride (Tanaka, Abe et al. 2013). During childhood the metabolic 
phenotype in PWS is more favourable compared to obese controls (Haqq, Muehlbauer et 
al. , Brambilla, Crino et al. 2011). Even in early adult life, PWS patients maintain such 
favourable metabolic status (Talebizadeh and Butler 2005, Grugni, Crino et al. 2013, 
Lacroix, Moutel et al. 2014). As they get older, the adiposity and microvascular dysfunction 
increase to a critical level. High-energy gain and low energy expenditure may be the 
underlying cause of increased adiposity and obesity in PWS. 
Therefore it is very important to understand factors controlling the energy balance in PWS. 
To understand better the gaps in knowledge about PWS we performed this study to 
examine increased energy intake and decreased energy expenditure in PWS. Increased 
energy intake is believed to be related to high blood ghrelin level which may be due to 
poor ANS function in PWS as explained before. We therefore aimed to study acyl ghrelin 
profile related to a mixed meal, complete ANS functions and the correlation of two. 
Decreased energy burning may be at different modalities of thermogenesis and we aimed 
to measure all aspects of energy expenditure in PWS. Because hypothalamus controls 
energy usage through ANS, we aim to correlate energy expenditure to ANS output. 
 
1.15: Hypotheses 
Obesity in PWS is believed to be due to impaired energy homeostasis at hypothalamus 
level where there is imbalance in energy intake and energy expenditure. Hyperphagia in 
PWS is the cause of increased energy intake and it is thought to be related to high and 
unregulated ghrelin level seen in PWS, which drives insatiable appetite. ANS has a role in 
controlling ghrelin production during fasting and post-prandial periods. 
It is my hypothesis that, dysautonomia, as part of hypothalamic lesion in PWS, leads to 
abnormal ghrelin suppression. Furthermore, I hypothesize that the total EE and NEAT are 
reduced in PWS. Hypothalamus controls NEAT through ANS outflow. NEAT is dependent 
upon ANS, wakefulness, and ghrelin status. It is biologically possible that NEAT is low in 
patients with PWS. Hence, it led to my hypothesis that the total EE and NEAT are lower in 
PWS than the controls. The effect of low TEE and NEAT cannot be compensated by 
relatively higher fat free mass adjusted REE as previously reported (van Mil, Westerterp et 
al. 2000, Goldstone, Brynes et al. 2002). 
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Chapter 2: ANS function and acyl ghrelin in children PWS 
 
2.1: Introduction  
ANS in PWS 
 Autonomic nervous system has been shown to control plasma ghrelin level as described 
in the introduction section of the thesis.  
A number of studies reported that there is likely to be ANS dys-function in PWS (DiMario, 
Bauer et al. 1993, DiMario, Dunham et al. 1994, DiMario and Burleson 2002, Purtell, 
Jenkins et al. 2013). Di Mario et al. performed a case- control study (DiMario, Dunham et 
al. 1994) and demonstrated lower resting diastolic blood pressure and lower change of 
orthostatic diastolic blood pressure in children with PWS. In the study, seven participants 
out of fourteen with PWS had pupillary constriction after Pilocarpine topical eye drops but 
none of the controls did. However, the results of measures of autonomic functions were 
inconsistent. Lower resting diastolic pressure and lower orthostatic change in blood 
pressure suggest poor sympathetic function and absence of pupillary constriction in fifty 
percent of the PWS participants suggest that local muscarinic acetyl choline receptors are 
defective rather than the central parasympathetic failure. A case- control study of PWS 
and controls (DiMario and Burleson 2002) did not find any difference in cutaneous blood 
flow as a response to change in body temperature. In another case- control study of PWS 
and controls, PWS patients had sinus arrhythmia with higher heart rate but less variability 
than controls (DiMario, Bauer et al. 1993). 
Purtell et al. also studied ANS function in PWS and described findings indicating poor ANS 
function in PWS.  The study used SphygmoCor (AtCor Medical, Sydney, NSW, Australia) 
to measure heart rate variability and arterial stiffness in adults with PWS and healthy 
obese controls (Purtell, Jenkins et al. 2013). The participants were then given a mixed 
meal to stimulate ANS function and the measurements were repeated at 30, 60, 120, 180 
and 240 minutes after the meal. The study found that the parasympathetic function in 
PWS group was indifferent to the controls but low frequency heart rate variability, which is 
dependent upon both parasympathetic and sympathetic outflow, was reduced. The 
authors therefore assumed that sympathetic function might be suboptimal in PWS. The 
study examined a single target organ, the heart which has dual ANS innervation. The 
activation and inhibition of sympathetic and para- sympathetic systems occur very quickly 
and frequently at times; and slowly and in sustained fashion at another times (Saul, 
Albrecht et al. 1988, Thomas 2011). For this reason it may be very difficult to study the 
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ANS function on a single organ at a single time point.  
Therefore, more data on ANS function in PWS may fill the gap in knowledge which in turn 
may result in possible treatment for PWS. 
Autonomic nervous control on orthostatic blood pressure 
Changing position from lying to standing normally increases the heart rate and systolic 
blood pressure within seconds followed by fluctuating decline thereafter even below the 
resting supine measurement (Borst, Wieling et al. 1982, Borst, van Brederode et al. 1984).  
The diastolic pressure behaves similarly but it reverts back to that of supine position after 
maximum heart rate has been achieved (Borst, Wieling et al. 1982, Borst, van Brederode 
et al. 1984). The effect of standing from the supine position is augmented by a preceding 
rest but not influenced by physical training. Compression of the blood vessels by the 
contracting postural muscles such as calf muscles leads to immediate rise in blood 
pressure. Acceleration of heart rate on rising is a reflex as active muscle contraction 
stimulates sympathetic nervous system and inhibits parasympathetic nervous system 
(Borst, Wieling et al. 1982, Borst, van Brederode et al. 1984).  
The drop in blood pressure after standing is sensed by the baro- receptors at the Carotid 
sinus and the heart that carry the signals to Nucleus Tractus Solitarius by 
Glossopharyngeal and Vagus nerves respectively. The neurotransmitter involved is L- 
glutamate.  NTS relays signals from glossopharyngeal and vagus nerves to PVN and SON 
of hypothalamus via A1 fibers and to the thoracic spinal cord via C1 fibers. The neurons of 
the NTS connect to C1 fibers by means of neurotransmitter GABA. The C1 neurons 
project to the intermediolateral and intermediomedial levels of the spinal cord, which then 
relay to either adrenal medulla or sympathetic ganglion where noradrenergic and 
adrenergic post- ganglionic neurons arise to innervate target organs such as blood vessels 
and cardiac muscles (Andersson, Cabero et al. 1996). (Figure 4) Hence orthostatic 
stimulation is a way to assess sympathetic nervous function (Hall 1988).  
 
Post- prandial ANS stimulation 
There have been a number of publications on the Sympathetic nervous stimulation after a 
meal. In a descriptive study, eight healthy young participants had radio- nucleotide 
cardiography in supine position before and after a standard meal. The meal increased the 
stroke volume and ejection fraction indicating positive inotropic and chronotropic effects of 
a meal. The study also showed there was dilation of left ventricle appreciably. It indicated 
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stimulation of sympathetic nervous outflow (Kelbaek, Munck et al. 1989). The same group 
studied thirty- six patients who recently had the first acute myocardial infarction (Kelbaek, 
Gjorup et al. 1989). After one month from hospital discharge, the participants who had 
acute myocardial infarction were randomized to meal and no meal groups. On supine 
position, all subjects had heart rate monitored by three- leads electrocardiogram, mean 
blood pressure determined by auscultation method, cardiac output measured by 
radionuclide cardiography, and venous plasma catecholamine measurement. There were 
no significant haemodynamic changes in those who had no meal but increased stroke 
volume; higher heart rate and cardiac output were noted in those who had had a standard 
breakfast. 
Scott et al. reported that carbohydrate ingestion increased muscle sympathetic nerve 
activity and calf blood flow (Scott, Greenwood et al. 2013). In the study, the authors 
showed that after carbohydrate ingestion, sympathetic nervous outflow was even higher in 
subjects with congestive heart failure than controls. Patients with congestive heart failure 
are considered to have higher sympathetic activity. Cox et al. (Cox, Kaye et al. 1995) 
studied normal healthy and lean participants on the meal effect on Sympathetic nervous 
function. After a meal, the Peroneal nerve sympathetic nerve activity increased from 7.7 
burst per minute to 17.9 bursts per minute and the total body noradrenaline spill over from 
neurons correspondingly increased from 24% to 56%. Another group (Sidery, Cowley et al. 
1993) also studied 10 healthy individuals by giving high carbohydrate meal and high fat 
meal. The authors showed that the sympathetic nervous system was stimulated after both 
high carbohydrate and fat meals. Cardiac output increased by 32% and 22% above the 
pre-meal state in the participants after a high carbohydrate meal and a high fat meal 
respectively. Fifteen minutes after high carbohydrate intake, the blood flow in superior 
mesenteric artery also rose by 87% and by 122% after high fat intake. In another study 
(Ryan, Goldberger et al. 1992), the authors described post-prandial sympathetic activation. 
The authors compared the cardiovascular response to a meal in young healthy individuals 
and ambulatory elderly individuals. The authors assumed there was blunting of 
sympathetic function in elderly population. Their primary outcome measure was post-
prandial change in beat- to- beat heart rate variation, using Heart rate spectral analysis of 
a Holter monitor, and blood pressure in the two groups of participants. In young 
participants, the low-frequency HR power and the low to high frequency band ratio 
increased suggesting activation of sympathetic nervous system. The elderly group did not 
have such response after a meal. Furthermore, the elderly group had significant drop in 
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blood pressure after a meal indicating poor sympathetic activation.  
Furthermore another study investigated the post meal sympathetic activation amongst 
patients with chronic ANS insufficiency presenting with idiopathic orthostatic hypotension, 
patients who had surgical sympathetectomy for uncontrolled hypertension, and one patient 
with pheochromocytoma on phenoxybenzamine, alpha adrenergic receptor blocker, 
against healthy controls (Robertson, Wade et al. 1981). After a mixed meal the mean 
arterial pressure dropped by 42 mmHg and 28 mmHg in sympathectomy group and a 
patient on phenoxybenzamine for pheochromocytoma respectively. The control group had 
mean increase of systolic blood pressure by 1 mmHg and diastolic pressure by 4 mmHg 
after a mixed meal. The study concluded that there was activation of sympathetic nervous 
system after a meal and it was blocked by surgical sympathectomy, and a sympatholytic 
agent.  
Therefore, a meal can stimulate sympathetic outflow and is useful in examining the 
function of the latter. 
Role of ANS in suppressing ghrelin 
Autonomic nervous system has been widely accepted as a control mechanism for ghrelin.  
Lee et al. reported increased ghrelin levels in vagotomized rats (Lee, Wang et al. 2002). It 
must be noted that ghrelin was measured after 14 days post vagotomy and the finding 
could be due to chronic changes rather than immediate withdrawal of vagal input. In 
another animal study, when Vagus nerve was stimulated for both 30 and 90 minutes, and 
it lead to reduction in plasma ghrelin significantly (Murakami, Hayashida et al. 2002). The 
study did not assess the role of Vagus nerve in post- prandial suppression of ghrelin but 
indirectly suggested a role of Vagus nerve on ghrelin at resting state. In a human study 
authors used a modified sham feeding to induce vagal stimulation and assessed its effect 
on post- meal ghrelin suppression (Heath, Jones et al. 2004). Plasma ghrelin levels are 
responsive to short- and long-term nutrient fluctuation, rapidly decreasing with food 
consumption and increasing with food deprivation or weight loss. William et al. 
hypothesized a vagal contribution to both responses. Nutrient-related ghrelin suppression 
may be mediated by gastrointestinal load-related vagal afferent activity, or depend upon 
vagal efferent input to the foregut, where most ghrelin is produced. Similarly, the 
deprivation-induced ghrelin rise could require state-related vagal afferent or efferent 
activity. Hence, the authors examined the role of the vagus nerve in the regulation of 
plasma ghrelin by sampling blood from rats with subdiaphragmatic vagotomy and from 
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sham-operated controls over 48 h of food deprivation, and before and after gastric gavage 
of liquid diet. Vagotomy affected neither baseline ghrelin levels nor the suppression of 
ghrelin by a nutrient load. The food deprivation-induced elevation of plasma ghrelin levels, 
however, was completely prevented by subdiaphragmatic vagotomy. In a separate 
experiment, the deprivation-related rise in plasma ghrelin was substantially reduced by 
atropine methyl nitrate treatment, indicating that the response to fasting is driven by 
increased vagal efferent tone. The dissociation between nutrient load- and deprivation-
related ghrelin responses indicates that the regulation of circulating ghrelin levels involves 
separate mechanisms operating through anatomically distinct pathways (Williams, Grill et 
al. 2003). 
Eight healthy individuals had both oral fat loads alone or modified sham feeding followed 
by oral fat load one hour after modified sham feeding. In the study, modified sham feeding 
was applied as a mean to stimulate vagus nerve. Plasma ghrelin level got lower after both 
protocols but greater suppression of ghrelin was noted in modified sham feeding followed 
by oral fat load. The authors reported vagal stimulation increased the pre-meal ghrelin 
level and suppressed the post- prandial ghrelin secretion. The effect of meal might also 
have effect on sympathetic outflow (Bray 1991, Ryan, Goldberger et al. 1992, Scott, 
Greenwood et al. 2013) which might have contributed to the ghrelin suppression. Another 
study did not find sham feeding, chewing and spitting, in health subjects suppressed 
plasma ghrelin level in healthy participants (Erdmann, Lippl et al. 2003). Ten healthy 
normal weight volunteers had modified sham feeding to stimulate cephalic vagal output 
and gastric dilation by 300 ml of guar solution. Modified sham feeding resulted in slight 
increase, and gastric dilation had no significant effect in ghrelin level. A recent study 
investigated the role of central melatoninergic tone on ghrelin suppression in human 
(Schubert and Makhlouf 1993). The study measured fasting and postprandial plasma total 
ghrelin in participants with melanocortin 4- receptor mutation (MC4RM), simple obesity 
and lean controls. The fasting total ghrelin level and AUC reduced in obese and lean 
group but ghrelin suppression was attenuated in MC4RM. Therefore central 
melanocortinergic tone modulates total ghrelin suppression. 
Hyperghrelinaemia in PWS 
In patients with PWS, the appetite is insatiable (Holland, Treasure et al. 1993) and it is 
generally assumed to be due to high and unregulated orexigenic peptide ghrelin 
(DelParigi, Tschop et al. 2002, Haqq, Farooqi et al. 2003, Butler, Bittel et al. 2004, Erdie-
Lalena, Holm et al. 2006, Butler and Bittel 2007, Haqq, Grambow et al. 2008). However, 
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the direct causal link between high ghrelin level and increased appetite has not been 
proven to this stage. Only positive correlation was reported between blood ghrelin level 
and subjective rating of hunger in PWS (DelParigi, Tschop et al. 2002). DelParigi and 
Tschop et al. compared fasting plasma total ghrelin in PWS group and healthy controls 
(DelParigi, Tschop et al. 2002). The mean fasting plasma ghrelin in PWS group was 
significantly higher than the healthy control group. After adjusting for the percent body fat, 
hyperghrelinaemia in PWS group remained unchanged compared to the control group in 
the study. The authors also reported that there was positive correlation between plasma 
ghrelin level and subjective ratings of hunger.   Haqq and Farooqi et al. measured fasting 
serum ghrelin in children with PWS and compared to four weight matched control groups, 
normal weight control group, obese control group, children with melanocortin-4 receptor 
mutation group, and leptin deficient control group (Haqq, Farooqi et al. 2003). The fasting 
ghrelin level in PWS group is significantly higher compared to obese, melanocortin-4 
receptor mutation and leptin deficient control groups but was not significantly different to 
the normal weight controls.  
Choe et al. reported that 16 children with PWS had 2- 3 folds higher number of ghrelin 
expressing cells in the gastric fundus and 2- 3 times higher ghrelin level compared to the 
13 growth hormone deficient children, 10 obese controls and 19 lean controls (Choe, Song 
et al. 2005).  In an another case- control study, forty children with PWS were compared to 
the eighty seven healthy non- obese controls (Feigerlova, Diene et al. 2008). The authors 
reported that children and adolescents with PWS had significantly higher plasma ghrelin 
level than the controls. Plasma ghrelin level was higher in very young PWS children than 
the controls and the study concluded it could play a role in development of early obesity in 
PWS. 
 
Suppressing ghrelin in PWS  
A meal or glucose load can suppress ghrelin in patients with PWS but not to a degree 
seen in the unaffected individuals (Haqq, Stadler et al. 2003, Paik, Choe et al. 2006, 
Gimenez-Palop, Gimenez-Perez et al. 2007). Gimenez-Palop et al. described suppression 
of plasma ghrelin in a case-control study that involved 7 PWS adults, who were not on 
growth hormone therapy; 7 obese control; and 7 lean controls (Gimenez-Palop, Gimenez-
Perez et al. 2007). After a liquid meal, plasma ghrelin level in PWS got suppressed but it 
did in slower rate than that of the two control groups. 270 minutes after the meal the mean 
ghrelin AUC was higher than the obese control group.  The authors suggested that the 
attenuation of ghrelin suppression after a meal might have relationship with hyperphagia in 
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PWS. Haqq et al. used a mixed meal to suppress ghrelin in PWS in an uncontrolled study 
(n=11) (Haqq, Stadler et al. 2003). Three participants had significant post-prandial 
suppression but the rest had slower suppression. Paik et al., however, demonstrated poor 
post-prandial suppression of acyl ghrelin after oral glucose load in a case- control study on 
11 children with PWS and 10 simple obese controls (Paik, Choe et al. 2006). The mean 
post glucose load acyl ghrelin level in children with PWS was significantly higher than the 
obese controls. Fasting acyl ghrelin and change in acyl ghrelin after oral glucose load 
were found to be correlated to whole body insulin sensitivity in children with PWS. The 
current understanding of attenuated post- prandial suppression of ghrelin may be the 
explanation for poor satiation in PWS. 
 
Effect of growth hormone therapy on ghrelin suppression in PWS 
The current evidence of the effect of growth hormone therapy on ghrelin suppression in 
PWS is unclear. In a study, growth hormone therapy changed the ghrelin profile related to 
oral glucose load in PWS patients (Hauffa, Haase et al. 2007). The study included twenty-
eight children with PWS, and investigated the status of plasma total and acyl ghrelin, 
before and after commencement of growth hormone therapy. Suppression of total ghrelin 
after glucose load was further reduced to a lower degree after the commencement of 
growth hormone therapy. However, the degree of post- glucose suppression of acyl ghrelin 
appeared similar after the prolonged use of growth hormone.  In 2009 the same group 
published a letter that growth hormone therapy reduced the ghrelin status and it might 
pose as a confounder in studies on ghrelin status in PWS (Hauffa and Petersenn 2009). 
On the other hand, in one study, nine children with PWS who were younger than 3 years 
of age had two plasma ghrelin evaluations before and at median one year of growth 
hormone therapy (Feigerlova, Diene et al. 2008). In the study, the ghrelin levels were not 
significantly different before and after starting growth hormone therapy. In a randomized 
study, plasma ghrelin status in adult PWS participants did not change after 6 months and 
12 months of growth hormone therapy (Hoybye, Barkeling et al. 2003). Growth hormone 
therapy has not been shown to influence plasma acyl ghrelin in current literature. 
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2.2: Clinical Questions and Hypothesis  
1. Is there ANS dysfunction in PWS? 
2. Does ANS dysfunction have a causal role in fasting acyl ghrelin and post- prandial 
suppression of acyl ghrelin? 
Based on the available evidence, it is my hypothesis that in PWS, which is considered to 
be a hypothalamic disorder, there is ANS dysfunction and it in turn is the cause for poor 
ghrelin suppression in PWS. 
 
2.3: Methods 
Aims, study type and study populations 
The aims of the study: 
1. To compare ANS status at fasting and after a mixed meal in the PWS and control 
groups by examining three target sites of ANS, cardiovascular system for orthostatic 
change in pulse rate and blood pressure, stomach for gastrin production and chromaffin 
cells of adrenal medulla for catecholamine production. 
2. To compare the fasting and post-prandial acyl ghrelin (AG) levels in PWS and control 
groups. 
3. To correlate ANS function to the degree of AG suppression. 
 
The study is a case- control study and there will be PWS group and age, gender and body 
mass index matched control group with simple obesity (Non- PWS).  
 
Inclusion Criteria 
PWS group consisted of 16 genetically diagnosed patients. The control group comprised 
of age, gender and BMI matched obese children without PWS.  
This study was conceived and designed before the Commonwealth Government of 
Australia started to subsidized growth hormone to all children under 18 years with genetic 
diagnosis of PWS. At the time of the launch of the study, PWS participants were already 
on growth hormone therapy that posed as an unavoidable confounder of the study. 
 
Exclusion Criteria 
Any participants with history of having any type of Diabetes Mellitus, other hypothalamic 
pathologies such as cranial radiation, surgery or central neuronal disorders, use of 
Psychotrophics such as Risperidone, Selective Serotonin reuptake inhibitors, or use of 
pyschostimulants were excluded. 
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48 PWS patients who attended the PWS clinic at Mater Children’s Hospital were 
approached personally and by post. The first 16 agreed to participate were included in the 
study. There were 2 PWS participants of mixed Asian and Caucasian descent. The rest of 
PWS and the controls are Caucasians. One PWS patient with type 2 diabetes mellitus and 
one who was on psychotropic drug were excluded. Volunteers without features of and 
diagnosis of PWS were included as controls. Friends and siblings of PWS patients; and 
children who attend general endocrinology and obesity clinic were approached. Due to 
difficulty in recruiting controls, normal weight controls were not included in the study. 
 
Study design 
All participants were asked to have their regular food intake prior to the study and they 
fasted overnight for 10 hours during the night before mixed meal challenge test. The study 
was performed at Mater Children’s Hospital in the morning. The participants were asked to 
collect the first urine sample after waking for catecholamine measurement (Urine test). 
After arrival to the Mater Children’s hospital, the weight and height were measured to the 
nearest 0.1 kg and 0.1 cm. Then topical anaesthetic cream was applied at the site on the 
upper limb where an indwelling intravenous cannula was to be inserted. Then all 
participants had their body composition measured using Bodystat 1500®. Bodystat 1500® 
works by passing a safe, battery generated signal through the body and measures the 
bioelectrical impedance (BIA) at 50 kHz. The National Institutes of Health provided a 
consensus statement that BIA provides a reliable method of measuring body composition 
under most conditions (1996). BIA has been a simple and useful tool in both clinical and 
research settings (Kyle, Bosaeus et al. 2004, Verdich, Barbe et al. 2011). BIA was chosen 
to measure body composition because it is cheap and practical as a bed-side device. Dual 
energy X-ray absorptiometry, being superior to BIA, was not used because of its expense 
and radiation exposure. 
The participants had sequential pulse, and blood pressure taken at supine and standing 
positions (Cardiovascular Test). A cannula was inserted for blood samplings and 15 
minutes after cannulation a venous sample of blood was collected for fasting serum acyl 
ghrelin, catecholamine and gastrin (Blood test). Then a mixed meal, which was similar to a 
usual breakfast composing of 50 gm of Carbohydrate, 23.38 gm of protein and 13.38 gm 
of fat (Table 1 and 2) was given to the participants. After the meal, blood tests and 
cardiovascular tests were repeated at 10, 30, 60 and 120 minutes; and urine sample at 2 
hours.  
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Table 1.  
Contents of the mixed meal. 
 
Table 2. 
Components of the mixed meal. 
 
Percent change in pulse at 15 and 30 seconds of standing (%ΔP at 15 s and 30 s) was 
calculated from the difference in supine pulse rate to the pulse rates at 15 and 30 seconds 
after assumption of an upright posture. Similarly the percentage of change in diastolic and 
systolic pressures (% Δ in DBP and SBP) were calculated from difference between supine 
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to standing blood pressures respectively at 15 and 30 seconds of standing from supine 
position (Hall 1988). Furthermore, mean arterial pressure (MAP) and percent change in  
MAP were calculated at 15s and 30s after standing. Urinary catecholamine; ΔPR and ΔBP 
at 15 sec were measured to assess sympathetic nervous system. Plasma gastrin was for 
parasympathetic functions. 
 
Plasma acyl ghrelin  
Blood samples were collected in the presence of a protease inhibitor (1mg/ml, Pefabloc 
SC, Roche). Blood samples were spun immediately in a refrigerated bucket centrifuge for 
15 mins at 3000 x g. Plasma was removed and one half was acidified with 1N HCl to a 
final concentration of 0.05N HCl in order to protect the acyl moiety. Plasma (acidified and 
non-acidified) was aliquoted into 100ul lots and frozen on dry ice and stored at -80°C.  
Acyl ghrelin was measured in plasma using a commercial ELISA (Human Active Ghrelin 
ELISA, Millipore, catalogue number EZGRA-88K), which displays no cross reactivity to 
des-octanoyl ghrelin. Values were interpolated from a sigmoidal 4- parameter logistic 
equation (GraphPad Prism 5.0) and intra-assay coefficient of variation was 5.9%.  
 
Plasma gastrin 
Gastrin is a hormone produced from the G cells at the base of gastric pyloric glands. It 
stimulates gastric acid secretion and mucosal cell growth (Chu and Schubert 2012). Vagus 
nerve controls the gastrin secretion from the stomach. 
Plasma gastrin was assayed using the MP Biomedicals double antibody competitive 
radioimmunoassay.  The patient sample was incubated with anti-gastrin antibody (rabbit 
anti-human gastrin) and 125I-labelled gastrin which competed with gastrin in the patient 
sample for the antibody binding sites.  After incubation, separation of bound from free 
gastrin was achieved by precipitation of the antibody-bound gastrin with a second antibody 
- goat anti-rabbit antibody plus a precipitation accelerator- followed by centrifugation and 
decantation of the unbound gastrin in the supernatant.  The antibody-bound 125I- gastrin 
fraction was counted in a gamma counter and the counts for patients' samples were 
compared with those for a set of standards of known gastrin concentration.  As the 
concentration of gastrin in the sample increased, the radioactivity present in the precipitate 
decreased. 
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Table 3: Inter-assay variation of plasma gastrin assay.                                             (2012) 
Level Ng/L CV% 
L1 49 10.0 
L2 236 5.0 
 
 
Plasma catecholamine 
In human, catecholamine in circulation is mainly from the chromaffin cells of adrenal 
medulla. Adrenal catecholamine production results from two input pathways, sympathetic 
neurogenic input via splanchnic nerve to chromaffin cells (de Diego, Gandia et al. 2008) 
and local gap junctional coupling between chromaffin cells (Martin, Mathieu et al. 2001, 
Colomer, Desarmenien et al. 2009).  
Metadrenaline, Normetadrenaline, and 3-Methoxy Tyramine in plasma were measured by 
Liquid Chromatography mass spectroscopy (LC- MSMS). Following the addition of a 
combined deuterated internal standard, samples at a neutral pH, were extracted from 
plasma by loading onto activated mixed mode cation exchange SPE columns. The 
columns were washed to remove interfering substances and the plasma metadrenalines 
eluted. The extract was dried down at 60°C, reconstituted in mobile phase and 20µL is 
injected onto a HILIC column.  Multiple reactions monitoring (MRM) was then carried out 
for each individual analyte.  Cycle time between samples is 5 minutes. 
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 Table 4: Intra-assay precision of plasma metadrenaline and normetadrenaline 
               2 levels of Quality Controls were assayed 10 times in one run (2013). 
  
Analyte Quality control Mean SD CV% 
Metadrenaline Chromsystems 
QC1 
478 15 3.2 
Chromsystems 
QC2 
1765 20 3.1 
Normetadrenaline Chromsystems 
QC1 
719 25 3.5 
Chromsystems 
QC2 
8394 306 3.6 
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 Table 5: Inter-assay precision of plasma metadrenaline and normetadrenaline 
  2 levels Quality Controls were assayed over 20 runs (2013) 
 
Analyte Quality Control Mean SD CV 
Metadrenaline Chromsystem 
QC1 
464 26 5.6 
Chromsystem 
QC2 
1827 74 4.0 
Normetadrenaline Chromsystem 
QC1 
758 42 5.5 
Chromsystem 
QC2 
8556 376 4.4 
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Urinary catecholamine 
 Urinary-free catecholamines were extracted from urine and their concentration was 
determined by reverse phase isocratic High Performance Liquid Chromatography (HPLC) 
coupled with Electrochemical Detection (ECD). The extraction procedure involved two steps: 
cation exchange and alumina extraction. Urine was loaded onto disposable columns 
containing cation exchange resin; the resin bound catecholamines were then eluted with 
boric acid. Alumina was added to this eluate to extract the catecholamine, which were then 
eluted from the alumina by acetic acid. A small volume of this eluate was injected onto the 
isocratic HPLC system. A NovaPak C18 reverse phase column separated the individual 
catecholamine peaks and the internal standard peak (IS). Peak resolution was improved by 
the addition of an ion-pairing reagent, 1-octane sulphonic acid, to the mobile phase. The 
catecholamine (CATS) were quantitated by ECD where they were oxidized to their 
corresponding anthraquinones (i.e. the oxidation of the phenolic group) at a fixed voltage 
potential and subsequently reduced back to their original state. The resulting flow of electrons 
was measured as current. 
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Table 6: Inter-assay precision of urinary catecholamine 
BIORAD Lyphochek 1 and 2 urine QC’s were assayed over a 1-year period (2011) 
 
  Mean SD CV% n 
Noradrenaline 
(nmol/L) 
L1 256 13 5.0 70 
L2 1203 69 5.7 70 
Adrenaline 
(nmol/L) 
L1 72 6 7.8 70 
L2 454 30 6.5 70 
Dopamine 
(nmol/L) 
L1 427 36 8.4 70 
L2 3447 221 6.4 70 
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Autonomic nervous functions as measured by the orthostatic change in pulse rate and 
blood pressure at the fasting state and post- prandial stimulated states were compared 
between the PWS and control groups to examine the hypothesis. Fasting and post-
prandial plasma gastrin, and plasma and urine catecholamine were also compared 
between PWS and control groups to complement cardiovascular data.   
Fasting and post-prandial plasma acyl ghrelin levels, and the rate of post-prandial 
reduction in plasma acyl ghrelin were also compared between the groups. Simple 
correlation was used to assess if there was a relation between ANS function and acyl 
ghrelin profile. 
 
2.4: Statistics 
The primary outcomes of the study were the level of ANS stimulation and suppression in 
serum ghrelin level after a meal. There are no such data available in normal healthy 
population, thus the calculation of sample size using standard methods is not feasible. 
Nevertheless we know that if we have 16 children in each group (PWS and Controls) we 
will be able to detect a significant difference of 1 standard deviation in the primary 
outcome variable, if it exists. This would be clinically and biologically significant. This 
calculation is based upon the following:  
In any calculation the sample size (n) can be determined by 
n =16/ f2 
where f is defined as 
 
f =  biologically significant difference to detect 
      standard deviation of the parameter of interest 
 
Thus in the proposed study, if we power the sample size to detect 1 SD of difference. 
Hence f equals to 1 and n equals 16.  
 
SPSS statistics version 22 for Mac (IBM Analytic Software) was used to perform statistical 
tests.  Student t tests was used to compare the means of the cardiovascular data in which 
two tail p value of <0.05 to reject the null hypothesis. Biochemical data is not normally 
distributed and it is expressed as median and inter- quartile range. Mann- Whitney U test 
was performed to compare the PWS and control groups. To correlate the fasting plasma 
acyl ghrelin level, and the fasting percent change of pulse rate, Pearson’s correlation was 
used. Area under curves (AUC) for acyl ghrelin and gastrin were calculated using 
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trapezoid method and those were compared using Mann- Whitney U test as those were 
not normally distributed. AUC of analytes are described as median and 95% confidence 
interval. 
2.5: Ethical approval 
The study has been approved by the HREC of the University of Queensland (Reference 
No. 2010000367) and Mater Health Services (Ref No. 1654C).  
 
2.6: Results 
The characteristics of the participants are described in the table 7. The PWS group 
comprised of 16 genetically confirmed individuals (nine females and seven males) and the 
control group had 16 volunteers (six females and 10 males). Apart from three of the 
controls, no other participants in both PWS and controls were in puberty. Three of the 
PWS participants were on stable thyroxine therapy for central hypothyroidism. The median 
age of the PWS cohort was 9.32 years (Inter quartile range 5.29) and due to difficulty in 
recruiting matched controls, older volunteers were accepted as controls. The median age 
for control group was 12.16 years (inter quartile range 6.12, p = 0.078). The PWS 
participants are shorter compared to the controls. The median height Z score for PWS 
group was -0.39 (IQR 1.45) while that of the controls was 1.03 (IQR 1.61, p= 0.049). The 
weight Z score in PWS group was 1.05 (IQR 1.62) and for the controls, 1.26 (IQR 1.32). 
The difference between groups did not reach statistical significance (p value of 0.54). The 
median BMI Z score in PWS group was 1.50 (IQR 1.39) and the control group was 1.10 
(IQR 1.11, p = 0.423). The lean mass in significantly lower in PWS group compared to the 
control group (26.00%, IQR 12.48 and 44.84%, IQR 20.85 respectively, p= 0.013). 
Similarly, waist and height ratio as an indicator of adiposity, trends to be higher in PWS 
cohort. The median waist and height ratio in PWS group was 0.55 (IQR 0.27) and that of 
the control group was 0.5 (IQR 0.1, p = 0.055). PWS participants had been on stable 
growth hormone therapy and the mean plasma insulin-like growth factor 1 (IGF1) was 
within normal range in females but slightly higher than normal upper limit in males. The 
mean (SD) plasma IGF1 level for the whole group was 48.7 (28.2) nmol/l. The mean (SD) 
IGF1 level for male PWS participants was 47.6 (29.5) nmol/l (reference range: 34.9-45.2 
nmol/l) and that of female participants was 47.6 (28.7) nmol/l (reference range: 33.2- 54.4). 
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Table 7:  
Comparison of characteristics of the PWS and control groups 
 PWS Control p 
Age (Yr) 
Median (IQR) 
9.32 (5.29) 12.16 (6.12) 0.078 
Height Z score 
Median (IQR) 
-0.39 (1.45) 1.03 (1.61) 0.049 
Weight Z score 
Median (IQR) 
1.05 (1.62) 1.26 (1.32) 0.545 
BMI Z score 
Median (IQR) 
1.50 (1.39) 1.10 (1.11) 0.423 
Waist to height ratio 
Median (IQR) 
0.55 (0.27) 0.50 (0.1) 0.055 
Lean mass % 
Mean (SD) 
26.00 (12.48) 44.84 (20.85) 0.013 
 
 
2.6.1: Cardiovascular changes 
Orthostatic compensatory autonomic response was poor in PWS participants. In PWS 
group, the lying pulse rate was higher than control group at both fasting post- prandial time 
points. But both of the pulse rates at 15 and 30 seconds of standing are lower than control 
group although the difference does not reach statistical significance (Figure 5). In other 
words, the mean pulse rate was higher in PWS participants than the controls but 
physiological orthostatic rise in pulse rate was lower in PWS participants than the controls. 
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Figure 5: Comparison of pulse rates while recumbent and standing at 15s (A) and 30s (B). 
Pulse rate is higher at recumbent position but orthostatic rise is attenuated in PWS group. 
(A) 
 
(B) 
 
At the fasting state, the mean percent change in pulse rate at 30 seconds after standing 
from the recumbent position in PWS group is significantly lower than the control group. At 
15 second, PWS group’s mean percent change in pulse rate (SD) was 10.2 % (± 3.66) and 
the control group’s was 23.22 % (± 7.54, p= 0.111).  At 30 seconds, it was similarly lower 
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in PWS group than the control group (7.49 ± 3.42% and 28.9 ±5.06 respectively, p= 
0.001). 
After a mixed meal, it remained significantly lower at 10, 60 and 120 minutes in PWS 
group than the controls. At 10 minutes after a mixed meal, the mean percent change in 
pulse rate at 15 second after standing in PWS group decreased to 4.43% (± 3.56), and in 
the control group, it increased to 28.5% (± 6.68, p = 0.002). After 30 seconds of standing, 
it also decreased to 4.98 ± 5.60% in PWS group, and it increased to 32.04 ±7.29% in the 
control group (p = 0.006). 
The percent change in pulse rate continued to rise in controls but that of the PWS subjects 
continued to fall at 60 minutes after a mixed meal. At 15 second of standing, the percent 
change of pulse rate was 4.43 ± 4.27% for PWS cohort and 35.04 ± 11.6% in controls (p= 
0.013). At 30 seconds of standing, it was 4.55 ± 4.44% in PWS and 40.43 ± 10.17% in 
controls (p= 0.002). 
The rise in pulse rate after standing was sustained in the controls 120 minutes after a 
mixed meal, but not in PWS group. The percent change of pulse rate was 4.70 ± 3.44% 
and 4.45 ± 4.78% in PWS, and 24.30 ±3.41% and 30.12 ± 4.13% in controls at 15 seconds 
(p= 0.0005) and 30 seconds (p= 0.0006) after standing respectively. (Table 8, Figure 6 
and 7) 
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Table 8: 
Comparison of change in orthostatic pulse rate in PWS and control groups 
 PWS Control p 
Fasting 
 
   
% change at 15s 10.2  
(3.66) 
23.22  
(7.54) 
0.111 
% change at 30s 7.49  
(3.42) 
28.9  
(5.06) 
0.001 
10 minutes Postprandial    
% change at 15s 4.43 
(3.56) 
28.5  
(6.68) 
0.002 
% change at 30s 4.98 
(5.60) 
32.04 
(7.29) 
0.006 
60 minutes 
Postprandial 
   
% change at 15s 4.43 
(4.2) 
35.04 
(11.6) 
0.013 
% change at 30s 4.55 
(4.44) 
40.43 
(10.17) 
0.002 
120 minutes 
Postprandial 
   
% change at 30s 4.70 
(3.44) 
24.30 
(3.41) 
0.0005 
% change at 30s 4.45 
(4.78) 
30.12 
(4.13) 
0.0006 
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Figure 6: 
The comparison of trends of % change in PR at 15 s after standing from recumbent 
position. DPR 15s means percent change of pulse rate at 15 seconds of standing from 
that of recumbent position. 
* p= 0.006, $p<0.02, #p= 0.0005 
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Figure 7: 
The comparison of trends of % change in PR at 30 s after standing from recumbent 
position. DPR 30s means percent change of pulse rate at 30 seconds of standing from 
that of recumbent position. 
**p= 0.001, * p= 0.006, $p<0.02, #p= 0.0005 
 
     
 
 
With regards to change in systolic blood pressure (Table 9, Figure 8 & 9), the percent 
change in systolic pressure, after standing for 15 second from recumbent position, 
increased significantly 120 minutes after a mixed meal in the controls but it decreased in 
PWS group. It was 4.02 ± 4.08%, 1.60 ± 2.39%, 3.85 ±2.80% and -1.90 ±1.59% in PWS 
group at fasting, 10 minutes, 60 minutes and 120 minutes after a mixed meal. In the 
controls, it increased from 0.97 ± 3.32% at fasting state to 3.20 ± 2.12%, 5.10 ± 2.60% and 
4.39 ±1.91% at 10 minutes, 60 minutes and 120 minutes after meal (difference with PWS, 
p values = 0.58, 0.64, 0.75, 0.017 respectively). The percent changes in systolic blood 
pressure at 30 seconds after standing was 2.35 ± 2.48% at fasting in the healthy controls 
but was -6.03 ± 2.30% in the PWS group (p= 0.02). The difference at 10 and 60 minutes 
post meal did not reach statistical significance (0.20 0.20 ± 2.31, 1.81 ± 2.98% for the 
control and -0.28 ± 2.83%, -2.37 ± 1.33% for PWS group). But at 120 minutes post meal, 
the percent changes in systolic blood pressure increased significantly (3.02 ± 1.43%) but 
that of PWS group decreased further (-3.55 ± 1.89%, p= 0.013). 
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Figure 8: 
The comparison of trends of % change in systolic blood pressure at 15 s after standing 
from recumbent position. DSBP 15s means percent change of systolic blood pressure at 
15 seconds of standing from that of recumbent position. 
*p= 0.017 
 
          * 
  
 
 
Figure 9: 
The comparison of trends of % change in systolic blood pressure at 30 s after standing 
from recumbent position. DSBP 30s means percent change of systolic blood pressure at 
30 seconds of standing from that of recumbent position. 
#p= 0.02, @p=0.013 
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The difference in changes in diastolic blood pressure to standing did not reach statistical 
significance. In PWS cohort, the percent change in diastolic pressure at 15 seconds of 
standing was 7.89 ± 4.44%, 10.45 ± 5.58%, 7.67 ± 4.47% and 1.54 ± 4.15% at fasting, 10, 
60 and 120 minutes. For the controls, it was 10.24 ± 2.82%, 9.84 ± 7.19%, 13.34 ±5.05%, 
and 8.85 ± 3.49% respectively (difference to PWS group, p= 0.69, 0.95, 0.41, 0.20).  
Although it was not statistically significant, percent change in diastolic blood pressure at 30 
second increased at 10 minutes post meal but declined from then on in both of the groups. 
The magnitude of change in PWS is lower than the controls. After 30 seconds of standing, 
the percent change of diastolic blood pressure was -0.49 ± 2.87%, 5.94 ± 4.26%, 2.66 
±2.61% and -1.27 ± 3.44% at fasting, 10, 60 and 120 minutes in PWS group. Whereas for 
the controls, it was 5.41 ± 4.85%, 13.16 ± 5.52%, 10.29 ± 3.06% and 4.62 ± 5.08% at 
fasting, 10 minutes, 60 minutes and 120 minutes after a meal (p value for difference to 
PWS group: 0.28, 0.30, 0.07, 0.33).  
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Table 9: Comparison of orthostatic change in systolic blood pressure in PWS and control 
groups 
 PWS Control p 
Fasting    
% change at 15s 4.02 
(4.08) 
0.97 
(3.32) 
0.58 
% change at 30s -6.03 
(2.30) 
2.35 
(2.48) 
0.02 
10 minutes 
Postprandial 
   
% change at 15s 1.60 
(2.39) 
3.20 
(2.12) 
0.64 
% change at 30s -0.28 
(2.83) 
0.20 
(2.31) 
0.90 
60 minutes 
Postprandial 
   
% change at 15s 3.85 
(2.80) 
5.10 
(2.60) 
0.75 
% change at 30s -2.37 
(1.33) 
1.81 
(2.98) 
0.175 
120 minutes 
Postprandial 
   
% change at 15s -1.90 
(1.59) 
4.39 
(1.91) 
0.017 
% change at 30s -3.55 
(1.89) 
3.02 
(1.43) 
0.013 
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Table 10: Comparison of change in diastolic blood pressure in PWS and control   groups 
 PWS Control p 
Fasting     
% change at 15s 7.89 
(4.44) 
10.24 
(2.82) 
0.69 
% change at 30s -0.49 
(2.87) 
5.41 
(4.85) 
0.28 
10 minutes 
Postprandial 
   
% change at 15s 10.45 
(5.58) 
9.84 
(7.19) 
0.95 
% change at 30s 5.94 
(4.26) 
13.16 
(5.52) 
0.30 
60 minutes 
Postprandial 
   
% change at 15s 7.67 
(4.47) 
13.34 
(5.05) 
0.41 
% change at 30s 2.66 
(2.61) 
10.29 
(3.06) 
0.07 
120 minutes 
Postprandial 
   
% change at 15s 1.54 
(4.15) 
8.85 
(3.49) 
0.20 
% change at 30s -1.27 
(3.44) 
4.62 
(5.08) 
0.33 
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Figure 10: 
The comparison of trends of % change in diastolic blood pressure at 15 s after standing 
from recumbent position. DDBP 15s means percent change of diastolic blood pressure at 
15 second of standing from that of recumbent position. 
p= NS 
 
 
Figure 11: 
The comparison of trends of % change in diastolic blood pressure at 30 s after standing 
from recumbent position. DDBP 30s means percent change of diastolic blood pressure at 
30 second of standing from that of recumbent position. 
p= NS 
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Figure 12: 
Comparison of change in mean arterial pressure at 15 and 30 seconds of standing (* 
p=0.045). %DMAP means percent change of mean arterial pressure at standing position 
(15 and 30 seconds) from mean arterial pressure at recumbent position. 
 
Percent change of mean arterial pressure (MAP) at 15 second of standing was similar in 
both groups at fasting and 10 minutes post meal (Figure 12). The mean percent changes 
in MAP were 5.62 (SD13.67) % and 5.9 (SD 10.49) % at fasting; and 6.12 (SD 14.35) % 
and 6.27 (SD 13.19) % at 10 minutes post-meal in PWS and control groups respectively 
(p- NS). At 60 minutes post meal, PWS group’s percent change in MAP was 5.77 (SD 
13.28) % and for the controls, 9.33 (SD 12.19) % (p- NS). However at 120 minutes post 
meal, there was further decrease in percent change of MAP in PWS group [-0.24(SD 
10.62) % in PWS versus 6.69 (SD 8.16) %, p= 0.05].  
At 30 seconds of standing, the difference in percent change of MAP in both groups did not 
reach statistical significance at fasting and 10 minutes post meal time points [-3.31 (SD 
9.1) % and 2.82 (SD 11.38) % in PWS group; and 4.02 (SD 11.46) % and 6.58 (SD 11.04) 
% in the control group respectively] (Figure 12). But at 60 and 120 minutes post mixed 
meal, the percent change in MAP was significantly lower in PWS group [ 0.39 (SD 7.39)% 
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and -2.34 (SD 10.23)% in PWS group; and 6.19 (8.31)% and 3.68 (SD 9.51)% in control 
group respectively, p=0.045 and 0.05] (Table 10). 
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Table 11:  
Comparison of percent change in mean arterial pressure [mean (SD) %]  
 *P=0.045 
 **p= 0.05 
 15 second 30 second 
PWS Control PWS Control 
0 min 5.62 
(13.67) 
5.90  
(10.49) 
-3.31 
(9.10) 
4.02 
(11.46) 
10 min 6.12 
(14.35) 
6.27 
(13.19) 
2.82 
(11.38) 
6.58 
(11.04) 
60 min 5.77 
(13.28) 
9.33 
(12.19) 
0.39 
(7.39) 
6.19* 
(8.31) 
120 min -0.24 
(10.62) 
6.69** 
(8.16) 
-2.34 
(10.23) 
3.68** 
(9.51) 
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Our findings suggest that there is poor sympathetic nervous reflex response to standing in 
PWS group. Immediately after standing from recumbent position, the sympathetic nervous 
system gets stimulated to increase adrenergic tone and maintain the cardiac output to 
maintain adequate blood flow to all organs particularly to the brain (Borst et al., 1984; 
Borst et al., 1982). It is represented in control group by higher percent change of pulse 
rate and arterial blood pressures, that is higher pulse rate and blood pressure at standing 
than recumbent position. But in PWS group the homeostatic rise in pulse rate failed to 
occur after 30 seconds of standing at fasting state and all post-prandial time points. 
Orthostatic change in systolic blood pressure at 120 minutes post meal was also 
significantly lower in the PWS group than the control group who displayed physiological 
rise in systolic blood pressure. Similarly, orthostatic rise in mean arterial pressure after 30 
seconds of standing was lower in PWS group at 60 and 120 minutes post mixed meal. 
Although statistically insignificant, there was a trend towards lower orthostatic change in 
mean arterial pressure after 15 seconds of upright position at 120 minutes post meal. 
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2.6.2: Biochemical changes 
2.6.2.1: Plasma gastrin 
Figure 13: 
Comparison of plasma gastrin profiles in PWS and control groups  
   
At the baseline, plasma gastrin level was not different in both groups. Its level in both 
groups rose after the mixed meal but it rose even further in PWS compared to the control 
participants at 120 minutes after meal.  
The median fasting plasma gastrin levels were 50.00 ng/L (IQR 20) in PWS group and 
39.50 ng/L (IQR 25.75) in the control group (p 0.626). The control’s plasma gastrin level 
rose slightly at 30 minutes after the mixed meal to 88.00 ng/L (IQR 72.00) but that of PWS 
was higher at 170.50 ng/L (IQR 266.25). The difference did not reach statistical 
significance (p by Mann- Whitney U test = 0.37). At 60 minutes post- prandial time point, 
the median gastrin levels were 90.00 ng/L (IQR 53.00) and 100.00 ng/L (IQR 62.00) for 
PWS and controls respectively (p by Mann Whitney U test = 0.799). At 120 minutes after 
the mixed meal, the median plasma gastrin levels were 124.00 ng/L (IQR 98.50) and 
69.00 ng/L (IQR 43.00) in PWS and controls respectively.  The p value by Mann- Whitney 
U test is significant at 0.036 (Figure 13). 
Furthermore, plasma gastrin area under curve (AUC) was significantly higher in PWS 
group. AUC0-120 min for PWS and control groups were 13753.12 ng.min/L (95% CI 10196.83 
to 17309.42) and 9378.46 ng.min/L (95% CI 6865.26 to 11891.66) (p 0.045) (Table 11). 
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Table 12: 
Fasting and post-prandial plasma gastrin levels (ng/L) and gastrin AUC 0-120 min (ng.min/L) 
in PWS and control groups. The gastrin levels are expressed in median (inter- quartile 
range) and gastrin AUC 0-120 min with 95% confidence interval. 
 
 PWS Control p 
Fasting 
 
50.00 
(20.00) 
39.50 
(25.75) 
0.626 
30 min postprandial 170.50 
(266.25) 
88.00 
(72.00) 
0.370 
60 min 
postprandial 
90.00 
(53.00) 
100.00 
(62.00) 
0.799 
120 min 
postprandial 
124.00 
(98.50) 
69.00 
(43.00) 
0.036 
 
(P) gastrin  
AUC 0-120 min 
13753.12 
(10196.83 to  
17309.42) 
9378.46 
(6865.26 to 
11891.60) 
0.045 
 
 
2.6.2.2: Catecholamine’s 
The mean plasma normetadrenaline levels were 287.1 ± 18.55 pmol/L, 319.8 ± 22.53 
pmol/L, 298.2 ± 33.25 pmol/L, and 330.6 ± 29.1 pmol/L at fasting, 30 minutes, 60 minutes 
and 120 minutes after meal in PWS group. The levels were similar in the controls, 283.4 ± 
31.96 pmol/L, 288.6 ± 30.1 pmol/L, 269.7 ± 29.28 pmol/L and 279.8 ± 26.22 pmol/L at 
fasting, 30 minutes, 60 minutes and 120 minutes post meal (p value for difference 
between PWS group: not significant at all-time points). In similar manner, the mean 
plasma metadrenaline levels were not significantly different between the two groups. In 
PWS group, it was 190.2 ± 18.94 pmol/L at the fasting state, 174.9 ± 16.8 pmol/L at 30 
minutes post meal, 163.5 ± 13.28 pmol/L at 60 minutes post meal, and 165.4 ± 16.28 
pmol/L at 120 post meal whereas it was 191.5 ± 23.17 pmol/L at fasting state, 167.6 ± 
24.35 pmol/L at 30 minutes post meal, 144.2 ± 16.90 pmol/L at 60 minutes post meal, and 
181.5 ± 27.56 pmol/L at 120 minutes post meal (difference with PWS: p = not significant at 
all-time points). 
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Figure 14: 
Plasma normetadrenaline (A) and metadrenaline (B) profiles in PWS and control groups 
(A) 
  
(B) 
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Table 13: 
Fasting and post-prandial plasma normetadrenaline and metadrenaline levels in PWS and 
caontrol groups [mean and SEM]. The difference of both analytes at all time point do not 
reach statistical significance. 
 
 (P) normetadrenaline 
(pmol/L) 
(P) metadrenaline  
(pmol/L) 
 PWS Control PWS Control 
Fasting 
 
287.10 
(18.53) 
283.40 
(31.96) 
190.20 
(18.94) 
191.50 
(23.17) 
30 min 
postprandial 
319.80 
(22.53) 
288.60 
(30.10) 
174.90  
(16.80) 
167.60 
(24.35) 
60 min 
postprandial 
298.20 
(33.25) 
269.70 
(29.28) 
163.50 
(13.28) 
144.20 
(16.90) 
120 min 
postprandial 
330.60 
(29.10) 
27.98 
(26.22) 
165.40 
(16.28) 
181.50 
(27.56) 
 
 
Urinary catecholamines excretion however was higher in PWS than controls at both fasting 
and at 2 hours post meal. Mean urinary Vanillylmandelic acid and creatinine ratio was 2.45 
± 0.20 umol/ mol and 1.87 ± 0.17 umol/ mol at fasting state in PWS and controls 
respectively (p for the difference= 0.037). It was 2.68 ± 0.19 umol/ mol and 1.86 ± 0.19 
umol/ mol at 2 hours post- prandial time point in PWS and controls respectively (p for the 
difference= 0.006). At fasting, the mean urinary noradrenaline and creatinine ratio was 
24.15 ± 2.67 umol/ mol in PWS group, but in the controls, it was significantly lower at 
15.00 ± 1.63 umol/ mol (p for the difference = 0.006). It remained different at two hours 
post meal in two groups. Mean noradrenaline and creatinine ratio in urine was 39.57 ± 
4.05 umol/ mol in PWS group and 24.00 ± 4.84 umol/ mol in the controls (p = 0.020). 
Furthermore, mean urinary adrenaline and creatinine ratio while fasting in PWS cohort was 
2.62 ± 0.51 umol/ mol whereas it was 0.97 ± 0.16 umol/ mol in control cohort (p = 0.003). 
At two hours post meal, it continued to rise significantly in PWS participants. It was 8.63 ± 
1.90 umol/ mol in PWS group but 4.53 ± 0.93 umol/ mol in control group (p = 0.088).  
In PWS group, urinary excretion of dopamine, normetadrenaline, metadrenaline and 3 
methoxy tyrosine expressed as the analytes and creatinine ratios were 325.5 ± 38.57 
mmol/ mol, 0.12 ± 0.01 mmol/ mol, 0.07 ± 0.01 mmol/ mol and 0.10 ± 0.01 mmol/ mol at 
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fasting respectively. Those of the control group at baseline were similar at 252.9 ± 23.34 
mmol/ mol, 0.11 ± 0.01 mmol/ mol, 0.07 ± 0.01 mmol/ mol, and 0.08 ± 0.01 mmol/ mol 
respectively (p for difference between groups = 0.11, 0.49, 0.73 and 0.18). However, at 2 
hours after a mixed meal, urinary dopamine, normetadrenaline, metadrenaline and 3 
methoxy tyrosine excretion in PWS were higher than the controls. 2 hours post meal mean 
urinary dopamine and creatinine ratio was 296.0 ± 28.14 mmol/ mol in PWS and 227.0 ± 
26.16 mmol/ mol in controls (p = 0.085), mean urinary normetadrenaline and creatinine 
ratio was 0.15 ± 0.01 mmol/ mol in PWS and 0.11 ± 0.01 mmol/ mol in controls (p = 
0.016), mean urinary metadrenaline and creatinine ratio was 0.10 ± 0.02 mmol/ mol in 
PWS and 0.07 ± 0.01 mmol/ mol in controls (p = 0.20), and mean urinay 3 methoxy 
tyrosine and creatinine ratio was 0.12 ± 0.01 mmol/ mol in PWS and 0.07 ± 0.01 mmol/ 
mol in controls (p = 0.026). Early morning urine is the urine produced overnight which is 
stored in the urinary bladder and catecholamine level in it reflects the level of adrenergic 
activity during sleep. Early morning urine samples of PWS participants showed higher 
vanillylmandelic acid, adrenaline and noradrenaline than the controls (p<0.05). Therefore, 
it reflects higher catecholamine production during sleep and is unlikely that PWS 
participants are more acutely stressed than the controls. 
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Table 14: 
Fasting and post-prandial urinary catecholamines and creatinine ratios in PWS and control 
groups (mean and SEM)  
* p< 0.05 
**p<0.01 
 
 PWS 
 
Controls 
 Fasting 
 
120 min 
postprandial 
Fasting 120 minutes 
postprandial 
Vanillylmandelic 
acid 
(umol/mol) 
2.45* 
(0.20) 
2.68** 
(0.19) 
1.87* 
(0.17) 
1.86** 
(0.19) 
Noradrenaline 
(umol/mol) 
24.15** 
(2.67) 
39.57* 
(4.05) 
15.00** 
(1.63) 
24.00* 
(4.84) 
Adrenaline 
(umol/mol) 
2.62** 
(0.51) 
8.63 
(1.90) 
0.97** 
(0.16) 
4.53 
(0.93) 
Dopamine 
(mmol/mol) 
325.50 
(38.57) 
296.00 
(28.14) 
252.90 
(23.34) 
227.00 
(26.16) 
Normetadrenaline 
(mmol/mol) 
0.12 
(0.01) 
0.15* 
(0.01) 
0.11 
(0.01) 
0.11* 
(0.01) 
Metadrenaline 
(mmol/mol) 
0.07 
(0.01) 
0.10 
(0.02) 
0.07 
(0.01) 
0.07 
(0.01) 
3 methoxy tyrosine 
(mmol/mol) 
0.10 
(0.01) 
0.12* 
(0.01) 
0.08 
(0.01) 
0.07* 
(0.01) 
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Figure 15: 
Comparison of urinary catecholamines and creatinine ratios in the PWS and control 
groups 
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2.6.2.3: Plasma acyl ghrelin 
The mean fasting plasma acyl ghrelin was higher in PWS group than the controls but it 
decreased to similar levels at 60 minutes and 120 minutes after a mixed meal. The mean 
plasma acyl ghrelin levels were 764.2 ± 67.1 pg/ ml, 631.2 ± 54.2 pg/ ml, 490.1 ± 53.0 pg/ 
ml, 414.3 ± 43.9 pg/ ml, 304.3 ± 28.0 pg/ ml, and 283.0 ± 28.9 pg/ ml at fasting, 10 
minutes, 20 minutes, 30 minutes, 60 minutes and 120 minutes after a mixed meal in PWS 
group. In the control group the mean plasma acyl ghrelin levels were 517.2 ± 67.3 pg/ ml, 
473.4 ± 67.4 pg/ ml, 381.2 ± 56.1 pg/ ml, 313.8 ± 46.4 pg/ ml, 283.9 ± 38.2 pg/ ml, and 
279.6 ± 38.2 pg/ ml at fasting, 10 minutes, 20 minutes, 30 minutes, 60 minutes and 120 
minutes post meal (p values for the difference with PWS group= 0.021, 0.290, 0.647, 
0.245, 0.697, and 0.689).  
 
Table 15: 
The mean and SEM of plasma acyl ghrelin levels (pg/ ml) in PWS and control groups at 
fasting, 10 minutes, 20 minutes, 30 minutes, 60 minutes and 120 minutes after a mixed 
meal. (ns- Not significant) 
 PWS Control p 
Fasting 764.2 (67.1) 517.2 (67.3) 0.021 
10 min 631.2 (54.2) 473.4 (67.4) ns 
20 min 490.1 (53.0) 381.2 (56.1) ns 
30 min 414.3 (43.9) 313.8 (46.4) ns 
60 min 304.3 (28.0) 283.9 (38.2) ns 
120 min 283.0 (28.9) 279.6 (38.2) ns 
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Figure16: 
Comparison of fasting and post-prandial plasma acyl ghrelin in PWS and control groups 
  
The acyl ghrelin area under curve is higher in PWS group during the early post- prandial 
period. The median (IQR) acyl ghrelin AG AUC0-10min for PWS group was 6771.33 
pg.min/ml (3833.32) and for controls, 4888.33 pg.min/ml (3429.74) (p value by Mann- 
Whitney U test 0.035). The fasting acyl ghrelin level in PWS cohort is negatively correlated 
to percent change in pulse rate at 30 seconds after assuming standing position from lying 
at fasting state (r value    -0.518, p 0.04). 
The rate of fall of acyl ghrelin was faster in PWS. The median (IQR) rate of decrease in 
plasma level of acyl ghrelin for PWS was  - 3.47 (2.88) and controls, - 1.65 (2.38) 
pg/ml/min (p Mann Whitney U 0.006). 
 
2.7: Discussion 
The attenuated percent change in pulse rate after stimulation by a mixed meal suggests 
poorer sympathetic nervous function in PWS. The rise of systolic blood pressure in PWS 
group was also lower than the controls at 120 minutes after a mixed meal. Similarly, the 
mean arterial pressure did not rise during 15 and 30 seconds of orthostatic stimuli at 120 
minutes; 60 and 120 minutes after a mixed meal respectively. 
The neuronal component of sympathetic adrenergic action is believed to be responsible 
for the reflex homeostatic mechanism to maintain normal cardiac output and blood 
pressure. Hill et al reported the effect of gravity on circulation (Hill 1895, Hill and Barnard 
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1897). The authors studied the effects of gravity, anaesthetics, dividing vagi, dividing the 
spinal cord, dividing the splanchnics, asphyxia, and curare in intracranial and arterial 
pressures in animals. The animals were put on a tilting board with their legs strapped in 
extended position. When placed in the vertical feet- down position, the pressures dropped 
in the experimental animals. On restoring to the horizontal position, the pressures got 
restored to the original levels. After dividing spinal cord at 3rd to 6th dorsal vertebra, the 
orthostatic fall in the pressures were more pronounced. Division of splanchnic nerve 
produced similar drop in the pressures. Hill concluded that gravity was a cardinal 
hydrostatic force in conditions such as syncope and shock, and that the splanchnic vaso- 
motor compensatory mechanism was important. Standing up reduces venous return to the 
heart by pooling blood at the dependent parts of the body. The afferent signals carried by 
Vagus nerve to the baro- receptors in the brain. The efferent adrenergic neurons increase 
the heart rate, cardiac output, and vascular resistance (Andersson, Cabero et al. 1996).  
In a human study (Kelbaek, Munck et al. 1989), twenty three healthy subjects without past 
history of syncope underwent tilt table test. Transient fall of blood pressure was noted 
during 70-degree upright tilt. There was negative association between blood pressure and 
calf blood flow. The calf vascular resistance was also found to be higher during upright 
position compared to supine position. The authors concluded that transient orthostatic 
hypotension occurs in healthy individuals. Increasing heart rate, stroke volume and 
vascular tone was the counter regulatory mechanism to correct it. The Sino- atrial node is 
the intrinsic pace maker of the heart and it connects to the Atrio-ventricular node and 
bundle of His. The conducting system then divides into Purkinje system that innervates 
cardiomyocytes. Sympathetic nervous system increases the discharge of the conduction 
pathway to induce inotropic and chronotropic action. Such reflex counter- regulatory 
mechanism is controlled by thoraco- lumber region of the spinal cord. The mechanism is 
by activating sympathetic nervous outflow. Another study described sympathetic response 
contributed to increase in vasomotor tone at the time of orthostatic hypotension (Kelbaek, 
Gjorup et al. 1989). Ten young and healthy volunteers had tilt table testing in thermal 
neutral environment (20- 24° C) after a light meal to study the sympathetic function. 
Clonidine, a central adrenergic blocker, was also given to assess the effect of absence of 
sympathetic function. When the arterial pressure dropped during head- up tilt, the cardiac 
output, heart rate and femoral blood flow rose briefly. Total vascular conductance followed 
the pattern exhibited by cardiac output. Clonidine blunted the reflex vasomotor responses 
to correct orthostatic hypotension. The effects of the counter regulatory mechanism began 
to be evident at 10 to 15 seconds and completed within 30 to 60 seconds after standing 
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(Erdmann, Lippl et al. 2003). In our study, post- prandial increase of heart rate after 
standing, systolic blood pressure at 120 minutes and mean arterial pressure at 60 and 120 
minutes after meal were lower in PWS group suggesting blunted reflex sympathetic 
vasomotor response. Our finding supports the Di Mario et al and Purtell et al (DiMario, 
Bauer et al. 1993, DiMario, Dunham et al. 1994, DiMario and Burleson 2002, Purtell, 
Jenkins et al. 2013). Di Mario et al. studied ANS function in PWS examining respiratory 
sinus arrhythmia (DiMario, Bauer et al. 1993) and reported that the pulse rate was 
generally higher than the controls but was significantly less variable to the change in intra- 
thoracic pressure associated with breathing. The finding in our study is similar to Di 
Mario’s study. The pulse at recumbent position is higher than the controls and it is less 
variable to the orthostatic stress.   
Interestingly, post-prandial plasma gastrin levels in PWS group were higher than controls. 
Both the post- prandial gastrin AUC 0-120 min and the median plasma gastrin level at 120 
minutes post meal were significantly higher in PWS group than the controls. High gastrin 
level is commonly observed in human and animals after vagotomy. Vagotomy was the 
surgical treatment for peptic ulcer disease many years back before the discovery of the 
aetiological role of Helicobacter pylori. There are many papers that studied effect of 
vagotomy procedure on plasma gastrin in human and animal models.  
In a study, thirteen vagotomised rats and twelve sham operated rats were fed using intra-
gastric infusion of liquid meal (Ami, Doi et al. 1993). Plasma gastrin levels increased after 
the liquid meal in both vagotomised and sham operated rats but the levels were 
significantly higher in the vagotomised rats. A similar study on vagotomised dogs also 
showed higher plasma gastrin level after meal (Eysselein, Niebel et al. 1985). The study 
also investigated the effect of Superior mesenteric and coeliac ganglionectomy disrupting 
sympathetic nervous supply to the stomach and small intestine on food related gastrin 
release. No effect of local sympathetic nerve disruption was noted on the gastrin release. 
Furthermore, Takeuchi et al studied male Sprague- Dawley rats and vagotomised animals 
had higher plasma gastrin level than sham surgery group (Takeuchi, Speir et al. 1980). 
Gastrin binding capacity as indicated by its receptor expression also increased in 
vagotomised animals. In another animal study, plasma gastrin level rose 12 weeks after 
the Proximal Gastric Vagotomy (Reina, Lopez-Cantarero et al. 1997). In another study, 
human patients who had had Vagotomy and Pyloroplasty for Peptic ulcer disease had 
higher plasma gastrin level than pre-operative levels (McGuigan and Trudeau 1972). The 
plasma gastrin level was reduced after Vagotomy and Antrectomy in the study as the 
numbers of the antral G- cells, which produce gastrin, were reduced after Antrectomy. The 
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authors explained that the reduction in gastric acid- pepsin secretion, and lack of Vagal 
inhibition might be the likely mechanisms by which gastrin was stimulated after Vagotomy. 
Similarly, Busman et al compared the pre- Vagotomy and post- Vagotomy plasma gastrin 
levels in 262 patients (Busman, Brombacher et al. 1987). The mean gastrin level after 
highly selective Vagotomy was significantly higher than the pre- operative level.  
PWS gene region contains Gamma Amino Buteric Acid (GABA) receptor genes (GABRB3, 
GABRA5, and GABRG3) (Cassidy and Driscoll 2009, Rout, Abdul-Rahman et al. 2012). 
Those genes are not imprinted and have bi- parental expression in normal individuals. 
Therefore genetic deletion of the region would reduce the expression of GABA-A 
receptor’s α5, β3 and γ3 subunits. GABA receptors are expressed in central nervous 
system, testes, heart, lungs, pancreas, intestine, kidneys and adrenal glands. Mice with 
GABA receptor β3 gene deficiency suffer from hypotonia and neuro- behavioural problems 
similar to PWS (Hashemi, Sahbaie et al. 2007). Using [11C] flumazenil (FMZ) positron 
emission tomography of the binding sites of benzodiazepine, Lucignani et al assessed the 
presence and number of cerebral GABA-A receptors in patients with PWS (Lucignani, 
Panzacchi et al. 2004).  The patients had reduced 11C FMZ binding predominantly in the 
cingulate, frontal and temporal cortices, and insula compared to unaffected participants of 
the study. The study concluded that there was altered GABA-A receptor composition or 
number in the cortical regions. A study supported the finding of Lucignani by reporting 
higher plasma GABA level in PWS (Ebert, Schmidt et al. 1997). The mean plasma GABA 
level in PWS and Angelman syndrome was two to three times higher than that of 
moderately obese and developmentally appropriate individuals or non- obese and 
developmentally delayed individuals. This finding confirmed that the GABA-A receptor 
configuration and its number were affected in PWS. Plasma GABA level is significantly 
higher and it exerts its effect on normal population of GABA-B receptors in PWS. In an 
animal study, stimulation of GABA-B receptors by Baclofen resulted in a clinical features 
similar to PWS such as reduced cognition, antinociception, muscle relaxation, decreased 
hormone production, increased food intake, and reduced intestinal peristalsis (Saffouri, 
Weir et al. 1980).  
GABA is the cardinal neurotransmitter at the Nucleus Tractus Solitarius and C1 area of the 
brain stem. C1 neurons connect to thoracic spinal cord and control the sympathetic 
discharge to cardiovascular tissues and adrenal medulla (Yamada, Norman et al. 1982). 
Therefore, our findings of poor sympathetic nervous function after a mixed meal may be 
due to abnormal GABA-ergic action at NTS. 
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Since GABAergic system also has the inhibitory function, there may be poor inhibitory 
action of vagus nerve similar to post- vagotomy state. The plasma catecholamine levels 
were similar in both groups but the urinary catecholamine excretions were significantly 
higher in the PWS group. Plasma catecholamine levels are generally tightly regulated. 
Generally urinary catecholamine represents catecholamine production. In the PWS group, 
the urinary levels were higher in both at the pre- and post- prandial periods. Since the first 
urine sample was collected after waking, it reflects the catecholamine production over 
night. Therefore, higher urinary catecholamine levels in PWS group is unlikely to be due to 
acute stress reaction. The main source of blood catecholamine is from the adrenal medulla 
but the spill over of those from the nerve cells is significantly less than adrenal origin. 
Adrenal medulla synthesizes noradrenaline and adrenaline from tyrosine. It is metabolized 
by catechol-O- methyl transferase (COMPT) or mono- amine oxidase (MAO), sulfated and 
excreted in urine, or re-uptake from the nerve endings. Adrenal catecholamine release is 
controlled by co-ordination of two input pathways. Pre-ganglionic sympathetic neuron 
innervates the adrenal medulla (de Diego, Gandia et al. 2008) and the intercellular gap 
junction stimulation among chromaffin cells (Guerineau and Desarmenien 2010). Mature 
sympathetic neurons synthesize brain- derived neurotrophic factor (BDNF) and pre-
ganglionic neurons express full- length trkB BNDF receptors. BNDF supports the growth 
and survival of preganglionic sympathetic neuron that innervate the adrenal medulla 
(Schober, Wolf et al. 1998). Endogenous release of acetyl choline acting on the 
muscarinic receptors at the splanchnic- chromaffin cell synapse releases catecholamine 
from chromaffin cells (de Diego, Gandia et al. 2008). The gap junction communication 
accelerates when there is reduction in cholinergic synaptic transmission (Martin, Mathieu 
et al. 2001, Khasar, Green et al. 2003, Martin, Mathieu et al. 2003, Colomer, Martin et al. 
2012). Among newborn rat, in which cholinergic synaptic transmission has not yet 
matured, there is increased gap junction stimulation between chromaffin cells (Martin, 
Mathieu et al. 2003). Moreover, chronic blockade of synaptic transmission after surgical 
denervation of the adrenal gland also resulted in increased dye coupling between 
chromaffin cells indicating increased communication. AO Martin et al. (Martin, Mathieu et 
al. 2003) blocked the post- synaptic nicotinic cholinergic receptor using Hexamethonium, 
Oxystillbene derivative F3 and snake neuro- toxin (α- bungarotoxin). Oxystillbene 
derivative F3 blocks the α3 subunit and α- bungarotoxin irreversibly antagonizes α7 
subunit of the nicotinic acetylcholine receptors. When adrenal medulla slices were 
incubated with the nicotinic cholinergic blockers, the spontaneous trans- synaptic electrical 
potential decreased but the intercellular communication between chromaffin cells 
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increased. Gap junction coupling probability, an indicator of inter- chromaffin cell 
communication, increased when hexamethonium and α- bungarotoxin, acetyl choline 
antagonists, were given to test animals (Colomer, Martin et al. 2012). Khasar et al 
described that vagotomised rats had higher plasma epinephrine (Khasar, Green et al. 
2003, Colomer, Martin et al. 2012). When compared to sham operation, the animals that 
had sub-diaphragmatic vagotomy had higher plasma epinephrine since day 3 of surgery. 
Our finding of higher production of catecholamine despite attenuated central sympathetic 
nervous function, as shown in our cardiovascular results, indicates the condition is similar 
to post- vagotomy state. Together with our finding of higher post- prandial plasma gastrin 
level, higher urinary catecholamine levels support that in PWS, there is vagal dysfunction. 
Watkins et al studied effect of vagotomy in adult male Sprague-Dawley rats on the pain 
sensation. The hyperalgesic effect of cytokine interlukin 1β was blocked by the surgical 
sub- diaphragmatic vagotomy (Scott, Greenwood et al. 2013). The classical PWS 
phenotype of high pain threshold may be due to Vagus-mediated effect on nociceptors 
and it supports our finding of vagal dysfunction. 
 
The median fasting plasma acyl ghrelin level in PWS group was higher than the control 
group. It got suppressed after the mixed meal and reached to similar level as controls after 
120 minutes. The rate of decrease of plasma acyl ghrelin was faster in PWS than controls. 
This is a novel finding that contrasts previous publications which reported partial 
suppression of ghrelin after a meal in comparison with the healthy controls. Haqq et al 
performed an uncontrolled study on 11 PWS participants (Haqq, Stadler et al. 2003). In 
eleven PWS subjects, total plasma ghrelin after an overnight fast got suppressed after a 
mixed meal by 35%. Gimmenez-Palop and group did a small case- control study on 7 
adult PWS patients and lean control group (Gimenez-Palop, Gimenez-Perez et al. 2007). 
The total plasma ghrelin was higher than the lean control group at fasting state and any 
time point after a liquid meal. The ghrelin AUC 0-6 h remained higher in PWS compared to 
obese and lean controls. Similarly Paik et al reported higher total ghrelin before and after 
oral glucose load (Paik, Choe et al. 2006). In the study, eleven children with PWS and ten 
normal obese controls underwent oral glucose test after an overnight fasting. Fasting 
plasma level of acyl ghrelin was higher in PWS compared to the controls. The nadir of acyl 
ghrelin post glucose load was 30 minutes for PWS and 90 minutes for the controls. The 
post- glucose load remained higher in the PWS group at all-time points till 120 minutes 
post glucose load.  
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Our PWS participants were already on growth hormone therapy at the time of study and 
had plasma IGF1 level in normal to even marginally higher range. A number of studies 
studied growth hormone’s effect on acyl ghrelin level in PWS. It was shown to have no 
effect on plasma acyl ghrelin in a study (Hauffa, Haase et al. 2007). Using oral glucose 
tolerance test, Hauffa et al investigated fasting and post glucose load plasma total and 
acylated ghrelin before and after commencement of growth hormone therapy. The median 
duration of growth hormone therapy was 1.18 years. Plasma acyl ghrelin levels did not 
change during oral glucose tolerance test before and after the commencement of growth 
hormone therapy. However, total ghrelin level declined after growth hormone therapy in 
PWS cohort. This result was conflicted by a case- control study that compared the fasting 
total plasma ghrelin before and after growth hormone therapy (Feigerlova, Diene et al. 
2008). The fasting total ghrelin level was not affected by the growth hormone therapy in 
children with PWS in the study. Hauffa et al later reproduced similar result to his previous 
study (Hauffa and Petersenn 2009).  Total ghrelin level but not acyl ghrelin level 
decreased after commencement of growth hormone therapy in children with PWS. In fact, 
plasma acyl ghrelin was similar before and after the growth hormone therapy. 
The fasting acyl ghrelin level in our PWS cohort is negatively correlated to the sympathetic 
nervous system function as indicated by percent change in pulse rate during fasting state. 
Autonomic nervous system has been thought to have a role on control of ghrelin. The 
exact mechanism of how ANS controls ghrelin remains unclear. It is very difficult to 
differentiate the sympathetic from para- sympathetic nervous functions, because ANS 
function is tightly controlled by reflex homeostasis and its effector organs are dually 
innervated. 
 
2.8: Conclusion 
Our data showed that there was defective autonomic nervous function in children with 
PWS, which in turn might have resulted in higher fasting plasma acyl ghrelin level.  Our 
cardiovascular data suggested homeostatic sympathetic function was at fault in PWS. Our 
biochemical data suggested that there was poor vagal inhibition on gastrin and 
catecholamine productions complementing the cardiovascular findings. Although the 
fasting plasma acyl ghrelin level was high, there was more rapid acyl ghrelin suppression 
after the mixed meal in PWS. At 60 and 120 minutes post meal, the acyl ghrelin level was 
similar to the controls. Fasting percent change in PR at 30s was negatively correlated to 
the fasting acyl ghrelin level. Therefore, poor ANS function in PWS may cause higher 
fasting acyl ghrelin. 
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Chapter 3: Energy Expenditures in PWS 
3.1: Introduction 
3.1.1: Global obesity 
Recent publication of the Australia Government indicated that one out of four children and 
three out of five adults are overweight or obese. There is 5% increase in prevalence of 
overweight or obesity since 1995 in Australia (Welfare 2013). Alike Australian data, obesity 
has been an escalating global burden (Ng, Fleming et al. 2014). It has been estimated to 
cause 3.4 million deaths, 3.9% loss of year of life, and 3.8% of disability- adjusted life- year 
worldwide (Ng, Fleming et al. 2014). The prevalence of overweight and obesity increased 
from 28.8% in 1980 to 36.9% in 2013 in adult men; and 29.8% in 1980 to 38.0% in 2013 in 
adult women worldwide in the study. Increased prevalence, not dissimilar to adults, is seen 
in children and adolescents especially in the developed countries. Currently the 
prevalence is 23.8% and 22.6% for boys and girls respectively in 2013 compared to 16.9% 
and 16.2% respectively in 1980 (Ng, Fleming et al. 2014). The prevalence of overweight 
and obesity in children and adolescents is also rising in developing countries. It was 8.1% 
in 1980 and increased to 12.9% in 2013 for boys, and similarly, 8.4% in 1980 for girls and 
13.4% in 2013 (Ng, Fleming et al. 2014). The fundamental cause of general childhood 
obesity is energy imbalance as a result of increased intake of nutrient rich food items 
(Parsons, Power et al. 1999, Swinburn, Egger et al. 1999, Caballero 2002, Story, Sallis et 
al. 2009, Cameron, Ball et al. 2012, WHO 2014) and low level of physical activity 
(Schlicker, Borra et al. 1994, Goran and Sun 1998, Ravussin and Gautier 1999, Boreham 
and Riddoch 2001, Lazzer, Boirie et al. 2003). Alarmingly, the overweight and obese 
children worldwide grow into obese adults (Delpeuch and Maire 1997, Kotani, Nishida et 
al. 1997, Rossner 1998, Imamura, Izawa et al. 2004, Juonala, Raitakari et al. 2006, 
Moayeri, Bidad et al. 2006, Cheng 2007). The prevalence of obesity in children has 
continued to rise despite good public awareness of complications related to it. 
 
3.1.2: Energy Expenditure 
Energy production, heat production or thermogenesis is essential for life. Animal and 
human cells produce heat by oxidizing foodstuff such as glucose, fatty acid and amino 
acids.  
Energy output can be generally divided in Basal Metabolic Rate, Activity related 
thermogenesis and Thermic effect of food. Because thermic effect of food intake is 
negligible, overall energy expenditure is dependent upon Basal Metabolic rate and Activity 
thermogenesis (Levine 2004, Levine 2004).  
91 
 
3.1.3: Resting Energy Expenditure or Basal Metabolic Rate 
Basal metabolic rate or resting energy expenditure is the rate of energy production at rest 
in the post- absorbed state in thermo- neutral environment (Himms-Hagen 1984). It is 
essential for keeping cells alive. The energy consumed in contraction of heart and 
respiratory muscles during resting ventilatory effort constitute resting energy expenditure. 
Change in resting energy expenditure, either increase or decrease, is slow (Himms-Hagen 
1984).  
Mitochondria are the organelles of all living cells that generate heat or energy including 
resting energy expenditure (Prusiner and Poe 1968).  The details of the mechanistic of 
energy production are explained below.  Prusiner and Poe also pointed out that 75% of the 
energy produced from mitochondria is free energy and 25% is conserved as ATP (Prusiner 
and Poe 1968). 
  
3.1.4: Activity Associated Energy Expenditure or Thermogenesis 
Muscle activity is the major source of energy production in human. The skeletal muscle 
activities associated with exercise, non- exercise movement or shivering contribute to the 
activity- associated thermogenesis. As myocytes contract energy is dissipated. When a 
motor nerve is stimulated the muscle fibers depolarize resulting in release of Calcium from 
intracellular stores. It leads to activation of myosin ATPase and, using the energy 
released, myosin molecules slide on the actin causing shortening of myofibrils (Ganong 
2001). Increased ADP supply from ATPase also accelerates mitochondrial oxidation, 
which further increases rate of combustion of fuel (Himms-Hagen 1976). The capacity of 
muscle to produce energy is not fixed. The muscles of trained athletes have better 
mitochondrial function and energy usage (Proctor, Sinning et al. 1995, Fernstrom, 
Tonkonogi et al. 2004). Morphometry of Vastus lateralis muscle of older individuals had 
decrease in size of the type II fibers responsible for fast twitch and oxidative capacity 
(Proctor, Sinning et al. 1995). In an another study, biopsy specimens of lateral aspect of 
quadriceps muscle showed significant increase in mitochondrial respiration and adenine 
nucleotide translocase after six weeks of endurance training (Fernstrom, Tonkonogi et al. 
2004). Mitochondrial content and oxidative capacity increase with exercise training. A 
sedentary muscle had only 65% of the electron transport chain complex content and lower 
maximum ATP production rate of an active muscle  (Conley, Amara et al. 2013).  Activity 
related thermogenesis can further divided into exercise associated (EAT) and non- 
exercise associated thermogenesis (NEAT) that is defined as energy expenditure related 
to activity other than volitional exercise (Levine 2004, Levine 2007). It includes fidgeting, 
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chewing gum, pacing around a room, toe tapping, shopping, dancing, gardening and so 
on.  In industrialized countries the non- exercise associated thermogenesis is the most 
important component of total daily energy expenditure. Even in avid exercisers, non- 
exercise associated thermogenesis is the most predominant component of total daily 
energy expenditure. Low non- exercise associated thermogenesis due to mechanization of 
day-to-day life can lead to obesity.  
 
3.1.5: Thermic Effect of Food 
There is increase in energy expenditure over several hours after eating and it is called 
Thermic effect of food. It is due to utilization of ATP in the metabolic disposal of ingested 
food such as digestion, storage or waste disposal.  For disposal of a molecule of glucose, 
2 to 4 molecules of ATP is used resulting in 5 to 10% loss of caloric value of the ingested 
carbohydrate (Himms-Hagen 1976). For lipid, 2 molecule of ATP or 1.4 to 4.6% of the 
energy acquired by ingesting lipid is used for disposal of free fatty acid or triglyceride 
(Himms-Hagen 1976). As for protein, 4 molecules of ATP or 20 to 30% of the energy 
acquired from the ingested protein is used for disposal of amino acids (Himms-Hagen 
1976). A small amount of energy is also used for transport of nutrients across intestinal 
wall (Schultz and Curran 1970).  
 
3.1.6: Mitochondria 
Mitochondria serve as generators of ATP and energy in every mammalian cell. 
Mitochondria are located in every cell of human and are involved in many cellular functions 
including production of energy and reactive oxygen species (Ganong 2001). Mitochondria 
have outer and inner membranes. The outer membrane is permeable to small metabolites 
but the inner membrane is controlled to maintain high electrochemical gradient created by 
the respiratory chain. It is important for energy production by oxidative phosphorylation. 
Nutrients are oxidized and yield electrons in the form of reduced Nicotinamide Adenine 
Dinucleotide (NADH) and Flavin Adenine Dinucleotide (FADH2). These reduced cofactors 
generate and transfer electrons to the electron transfer chain. The electron transfer chain 
activates pumping of protons across the inner membrane of mitochondria. The electron 
transfer chain comprises of five protein complexes on the inner membrane: complex I 
(NADH dehydrongenase), complex II (succinate dehydrogenase), complex III (ubiquinone 
cytochrome c oxidoreductase), complex IV (cytochrome oxidase), and complex V (F1F0-
ATP synthase). Complexes I, III and IV pump protons across the inner membrane as the 
electrons down the respiratory chain creating electrochemical potential gradient across 
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known as the proton motive force. The energy conserved from the membrane potential is 
used by the complex V to synthesize Adenosine tri- phosphate (ATP) from Adenosine di- 
phosphate (ADP). The energy derived is then dissipated out and released as heat (Echtay 
2007). In health, most adult produce approximately 65 kg of ATP per day powered by the 
mitochondrial respiratory chain (Rich 2003). 
 
3.1.7: Mitochondrial Uncoupling Proteins 
Mitochondrial membrane carriers facilitate specific exchange of molecules between cytosol 
of a cell and mitochondrial matrix to carry out metabolic pathways such as the citric acid 
cycle, fatty acid  oxidation, urea cycle, oxidative phosphorylation, and generation of heat 
by dissipation of the proton gradient. Uncoupling proteins (UCP) are members of 
mitochondrial carriers, and are proton carriers located on the inner membrane of 
mitochondria. UCPs have a tripartite structure that consist of three repeat domains each 
with two hydrophobic transmembrane - helice regions spanning the mitochondrial inner 
membrane. UCPs have both the N- and C- terminal ends facing towards the cytosolic side 
of the inner membrane. UCP -1 is specific for brown adipose tissue (BAT) but also seen in 
longitudinal smooth muscle layers of digestive, uterine and male reproductive tracts 
(Nibbelink, Moulin et al. 2001). Recent literature proved that not only human neonates but 
children, adolescents and even adults bear brown adipose tissue around neck, inter- 
scapulae area and axilla (Dawkins and Scopes 1965, Heaton 1972, Bouillaud, Combes-
George et al. 1983, Lean and James 1983, Lean, James et al. 1986, Bouillaud, Villarroya 
et al. 1988). Therefore thermogenesis by the UCP1 at BAT is significant in human 
neonates, children, adolescents and adults. 
UCP-2 is widely expressed in tissues including stomach, thymus, spleen, macrophages, 
hypothalamus and β cells of the pancreas (Azzu and Brand 2010). UCP- 3 is primarily 
seen in skeletal muscles but also in brown adipose tissue and heart (Azzu and Brand 
2010). 
The uncoupling of such protein is stimulated by fatty acids releasing heat. UCP1 mediates 
proton leak and it dissipates the proton motive force. It in turn reduces the number of 
proton flowing through the ATP- synthase. The leak of proton through UCP-1 uncouples 
substrate oxidation from phosphorylation of ADP to ATP. It leads to faster oxygen 
consumption and energy derived from the oxidation of the substrate is released as heat 
(Cannon and Nedergaard 2004). 
There are two classes of mitochondrial proton leak: basal and inducible (Thrush, Dent et 
al. 2013). Basal leak takes place in all tissues and no specific mechanism appears to 
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control the process (Thrush, Dent et al. 2013). It has been postulated that the basal leak 
facilitates energy expenditure by increasing sensitivity and decreasing the response time 
to change in the cellular ATP utilization (Rolfe, Newman et al. 1999). Inducible proton leak 
is catalyzed by the UCPs (Divakaruni and Brand 2011) and adenosine neucleotide 
translocase enzyme may be the control mechanism (Andreyev, Bondareva et al. 1988). 
Adenosine nucleotide translocase mediates ADP influx into mitochondrial matrix and efflux 
of ATP.  
 
3.1.8: Role of ANS in controlling UCPs 
Respiratory burst of UCP1 at brown adipose tissue increases in response to noradrenaline 
(Sluse, Jarmuszkiewicz et al. 2006). Brown adipose tissue is highly vascularized and richly 
innervated by the sympathetic nervous system. When BAT- bearing organisms such as 
human or grizzly bears get exposed to cold stress, sympathetic nervous system is 
activated and secretes noradrenaline (Smith and Horwitz 1969). When noradrenaline 
binds to 3 adrenoreceptors, it stimulates cyclic AMP- dependent liberation of intracellular 
free fatty acids, which in turn is a signal for activation of UCP1- induced proton leak and 
energy production (Jezek 2002). Moreover, activation of 1 adrenoceptor by noradrenaline 
potentiates the thermogenic function of 3 adrenoceptors (Zhao, Cannon et al. 1997).  
 
3.1.9: Role of sympathoadrenal system in Energy Expenditure 
Since 1950s it has been clearly shown that ANS has an important role in energy 
expenditure (Hsieh and Carlson 1957, Hsieh, Carlson et al. 1957). The authors 
demonstrated that cold- acclimatized rats with intact ANS but treated with curare, to inhibit 
shivering, maintained body temperature when the environmental temperature was lowered 
from 30ºC to 5ºC. It meant the thermogenesis or energy expenditure was not affected in 
those animal with intact ANS even though shivering was prevented. However, when the 
animals were given hexamethonium, an ANS ganglion blocker, thermogenesis was 
completely inhibited and the body temperature fell. Administration of noradrenaline 
restored the thermogenesis and prevented the drop in body temperature (Hsieh and 
Carlson 1957, Hsieh, Carlson et al. 1957). The uncoupling protein deficient mice 
consumed less oxygen after treatment with beta- 3 adrenergic receptor agonist and they 
are sensitive to cold exposure (Enerback, Jacobsson et al. 1997). 
Both sympathetic nervous system and adrenal medulla are stimulated during cold stress to 
increase thermogenesis (Therminarias, Chirpaz et al. 1979, Landsberg and Young 1983, 
Landsberg and Young 1984). The afferent neurons arising from the peripheral (skin) and 
95 
 
central (hypothalamus, and brain stem) relay thermal senses to anterior and posterior 
hypothalamus. The efferent fibers increase the sympathetic tone and in turn causing 
vasoconstriction, shivering, piloerection, and energy production (Gale 1973, Landsberg 
and Young 1983, Landsberg and Young 1984).  
In an animal study, it was shown that food induced thermogenesis involves sympathetic 
nervous system activation on BAT. The study also found that adrenergic drive increased 
resting oxygen consumption and inter- scapular BAT mass but a beta- adrenergic blocker, 
Propranolol, decreased the resting oxygen consumption (Landsberg and Young 1984). 
Noradrenaline is synthesized and stored in sympathetic nerve endings and upon 
stimulation; it is released to act on the post- synaptic adrenergic receptors. Adrenaline is 
the circulating hormone of the adrenal medulla. It is released into the blood stream for 
physiological functions. Hypothalamus and brain stem regulates the sympathetic 
adrenergic outflow.  
Mature sympathetic neurons synthesize brain- derived neurotrophic factor (BDNF) and 
pre-ganglionic neurons express full- length trkB BNDF receptors. BNDF supports the 
growth and survival of preganglionic sympathetic neuron that innervate the adrenal 
medulla (Schober, Wolf et al. 1998).  
 
3.1.10: Role of hypothalamo- pituitary- thyroid axis in control of energy expenditure 
Hypothalamo- pituitary- thyroid axis is also important in regulating energy homeostasis. 
Thyroid hormone influences energy production through its action on the hypothalamus 
effecting appetite, thermogenesis, locomotion and autonomic regulation (Lechan and 
Fekete 2006). Thyrotropin from hypothalamus stimulates anterior pituitary to secrete 
thyroid stimulating hormone which in turn regulates thyroid hormone synthesis from the 
thyroid gland. Thyroid hormone is important in sustaining body’s core temperature (Silva 
1995, Silva 2001, Bianco, Salvatore et al. 2002, Silva 2003). It increases thermogenesis 
by stimulating numerous metabolic pathways involved in development, remodeling, and 
delivery of energy to all tissues (Silva 1995). Thyroid hormone also interacts with 
sympathetic nervous system in generating facultative thermogenesis. When thyroid 
hormone function is completely blocked, resting energy expenditure can be reduced as 
much as 30% and homeostatic thermogenesis in response to cold exposure can be 
dampened (Silva 2003). On the other hand, hyperthyroidism increases energy expenditure 
by increasing ATP consumption (Silva 2003). Thyroid hormone has control on uncoupling 
proteins of mitochondrial inner membrane (Gong, He et al. 1997, de Lange, Lanni et al. 
2001, Lebon, Dufour et al. 2001). De Lange et al. administered T3 to hypothyroid rats and 
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demonstrated there was increased expression of uncoupling protein 3 in skeletal muscles 
resulting in increased resting metabolic rate (de Lange, Lanni et al. 2001).  Gong at al. 
quantified the uncoupling protein 3 in skeletal muscles (Gong, He et al. 1997). In 
hypothyroid rats, UCP3 decreased three folds whereas hyperthyroid rats had 6 folds 
higher. In a human study, healthy adults were given T3 for three days and it resulted in 
70% rise in the rates of ATP synthesis and tri-carboxylic acid cycle flux in skeletal muscles 
which was detected by nuclear magnetic resonance (Lebon, Dufour et al. 2001). Thyroid 
hormone also acts on uncoupling protein 1 in brown adipose tissue (Enerback, Jacobsson 
et al. 1997, Ribeiro, Carvalho et al. 2001, Bianco, Salvatore et al. 2002). Hypothyroid mice 
treated with T3 or thyroid hormone receptor beta selective ligand were found to have 
restored uncoupling protein 1 in brown adipose tissue between scapulae (Ribeiro, 
Carvalho et al. 2001). Subsequently, the hypothyroid mice, after being treated with T3 and 
infused with norepinephrine, had 3 degree Celsius elevation in body temperature but not in 
the THR beta ligand. Ribeiro et al. concluded that thyroid hormone stimulates UCP1 in 
BAT and augments adrenergic responsiveness in thermogenic tissues (Ribeiro, Carvalho 
et al. 2001). 
 
3.1.11: EE in PWS 
In growth hormone naïve patients with PWS, resting metabolic rate and average metabolic 
rate were found to be low in a study (Butler, Theodoro et al. 2007). However, the duration 
of the study was only 8 hours on each participants and the result may not represent the 
actual EE. When adjusted for lean body mass the TEE and REE are not different. Other 
studies found that the basal metabolic rates and activity associated energy expenditure 
were higher than the controls after being adjusted for the lean body mass in patients with 
PWS who were not on growth hormone therapy (van Mil, Westerterp et al. 2000, 
Goldstone, Brynes et al. 2002). Having obesity and relatively higher RMR (van Mil, 
Westerterp et al. 2000, Goldstone, Brynes et al. 2002) suggests that the activity 
associated energy expenditure must be definitely low in patients with PWS. EAT may be 
insignificant because patients with PWS rarely exercise (Davies and Joughin 1993, van 
den Berg-Emons, Festen et al. 2008). Therefore NEAT represents activity- associated 
thermogenesis in PWS and it is very likely to be low. ANS dysfunction and probably 
hyperghrelinaemia may be the causes of low NEAT in PWS.  
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3.1.12: Gap in knowledge 
Specific metabolic rate such as total, or resting or basal energy expenditures have been 
studied in PWS but not on the complete profile of all components of EE. Moreover, the role 
of ANS and ghrelin in EE in PWS remains unknown. 
 
3.2: Clinical Question and Hypothesis 
Since obesity is a common problem in PWS, the EE in children with PWS is expected to 
be low. A study showed lower unadjusted resting energy expenditure but another study 
showed better resting energy expenditure if adjusted for fat free mass. Having obesity and 
relatively higher REE for lean body mass in PWS patients suggest that the problem lies in 
the activity associated thermogenesis. Since most children with PWS have reduced 
physical activity (Davies and Joughin 1993, van den Berg-Emons, Festen et al. 2008), 
NEAT appears to be the main contributor of the activity associated thermogenesis. Since 
NEAT is dependent upon ANS and ghrelin status, it is biologically possible that NEAT is 
low in patients with PWS. This led to my hypothesis that the NEAT is lower in PWS than 
the controls which cannot be compensated by the relatively high REE for lean body mass. 
 
3.3: Aim, study type and populations 
The aim of the study is to compare the total and differential EE, measured during three 
consecutive days among PWS patients and controls. PWS group comprised of genetically 
confirmed patients. 48 PWS patients who attended the PWS clinic at Mater Children’s 
Hospital were approached personally and by post. The first 16 agreed to participate were 
included in the study. There were 2 PWS participants of mixed Asian and Caucasian 
descent. The rest of PWS and the controls are Caucasians. One PWS patient with type 2 
diabetes mellitus and one who was on psychotropic drug were excluded. Volunteers 
without features of and diagnosis of PWS were included as controls. Friends and siblings 
of PWS patients, and children who attend general endocrinology and obesity clinic were 
approached. Due to difficulty in recruiting controls, normal weight controls were not 
included in the study.  
 Growth hormone therapy in PWS cohort will be a confounder and should be an exclusion 
criterion. However, with the commencement of Australian pharmaceutical benefit scheme’s 
growth hormone therapy in all PWS patients, it would be difficult to recruit PWS 
participants who are not on growth hormone. Hence it may pose as a weakness of the 
study. Further exclusion criteria include any hypothalamic disorders, stimulant and 
psychotropic drugs use.  
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3.4: Statistics (EE study) 
The primary outcomes of the study are total and differential energy expenditures. A 
sample size of 16 in each group will allow a difference of 1 SD of energy expenditure 
between the two groups to be detected, if it exists (see statistics section of chapter 2). 
The energy expenditures are adjusted to both the body weight (Wt) and fat free mass 
(FFM) or lean mass for comparison between PWS and control groups. Log- log regression 
method was used for this purpose (Davies, Cole et al. 1989, Davies and Cole 2003). The 
energy expenditure was expressed as Kcal/ kg Wtp or FFMp. Logarithm value of energy 
expenditure; weight and FFM were calculated first. The log value of energy expenditure 
and log value of either weight or FFM were regressed. The value of p is the slope of the 
linear regression between either log of weight or FFM, and log of energy expenditure. By 
adjusting energy expenditure to Wtp or FFMp, it can be compared across different weight 
or body composition. 
For the purpose of measuring NEAT, the definition by Levine (Levine 2004) was used. A 
period of exercise was arbitrarily defined as “Sustained high energy expenditure with high 
physical activity level and heart rate for 30 minutes or more”. Available data suggests that 
children with PWS had reduced physical activity compared to unaffected children (Davies 
and Joughin 1993) in addition to muscle hypotonia (Prader, Labhart et al. 1956, Eiholzer 
2005, Cassidy and Driscoll 2009) and skeletal abnormalities (West and Ballock 2004, 
Kroonen, Herman et al. 2006).  Thence, children with PWS generally are not able to 
participate in usual sporting events or exercise programs that commonly last for 60 
minutes or more. To give children with PWS who participated in the study a sporting 
chance, only thirty minutes or more of high and sustained physical activity was defined as 
an episode of exercise. 
For comparison of energy expenditures adjusted to weight and FFM in PWS and control 
groups, Student t- test is used. SPSS statistics version 22 for Mac (IBM Analytic Software) 
was used to perform statistical tests.  Student t tests was used to compare the means of 
the cardiovascular data in which two tail p value of <0.05 to reject the null hypothesis. 
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3.5: Study design 
Figure 17: Actiheart 
 
 
Actiheart is 7 mm thick with a diameter of 33 mm and it houses a movement sensor a 
rechargeable battery, a memory chip and electronics (Brage, Brage et al. 2005). A wire, as 
shown in Figure 13, runs to a smaller clip that is placed around apex of the heart by means 
of an electrocardiograph adhesive pad. Actiheart measures acceleration, heart rate, heart 
rate variability and ECG amplitude. Actiheart measures heart rate and body movement to 
calculate energy expenditure (Crouter, Churilla et al. 2008). The memory chip can store 
data of EE and physical activity index of an epoch of 1 minute for more than 11 days. 
During physical activity, movement sends a voltage signal that is converted to a binary 
signal quantifying acceleration as numerical levels. It measures ECG signals that is 
electronically amplified by a factor of 900. It is converted to heart rate (beats per minute) 
and written to the memory at the end of each epoch. The measurable heart rate is 
between 31 to 250 beats per minute according to the manufacturer.  
Actiheart has been validated as a tool to measure energy expenditure (Brage, Brage et al. 
2005, Brage, Brage et al. 2006, Butte, Wong et al. 2010, De Bock, Menze et al. 2010, 
Adolph, Puyau et al. 2012, Campbell, Prapavessis et al. 2012, Villars, Bergouignan et al. 
2012).  Crouter and group validated Actiheart against Cosmed K4b (2) and the former 
provided similar calculation to the latter in different physical activities (Crouter, Churilla et 
al. 2008).  In a study, heart rate measurement by R- wave impulses using Actiheart agreed 
with electrocardiograph during rest and treadmill locomotion (Brage, Brage et al. 2005). 
There was strong linear relationship between movement and acceleration in the study. 
However, further studies are needed to validity in other activities and free- living. Adolph et 
al. validated actiheart, actical, RT3 accelerometer against room calorimetry. The authors 
found that the devices had similar accuracy for sedentary, light, moderate to vigorous 
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levels of physical activity (Adolph, Puyau et al. 2012). Furthermore, Butte et al. validated 
actiheart against doubly labeled water in children (Butte, Wong et al. 2010). The Bland- 
Altman plot in the study showed the value of total energy expenditure is in good 
agreement with doubly labeled water with no systematic bias.  In addition, another study 
found that lean and sedentary adults, tested for heart rate variation and physical activity 
using actiheart, had a good level of agreement in energy measurement with doubly 
labeled water (Villars, Bergouignan et al. 2012). 
All participants in our study were requested to have usual diet and physical activity for 24 
hours before the study. They presented to Mater Children’s Hospital in the morning for the 
testing. Then they had body composition measured using bio-impedance (Bodystat). 
Afterwards Actiheart was placed on the anterior chest wall with an aid of an 
electrocardiograph pad. Participants wore Actiheart for three days.  Children with PWS can 
have disturbing skin picking if an adhesive ECG pad is placed on the chest for a long time. 
Therefore, to obtain average EE over a long period, it was decided to measure EE using 
Actiheart for three days. Actiheart measures physical activity index, total EE and 
differential EE. After three days of recording energy expenditures, the device was 
uploaded to obtain the total and differential metabolic rates of the participants. The 
Actiheart estimated REE and AAT. Energy spent during exercise period was deducted 
from AAT to measure NEAT. The exercise periods were identified according to the 
definition described above and the energy used during the period was subtracted from the 
total activity associated thermogenesis to calculate for non- exercise associated 
thermogenesis as defined by Levine. The total and differential metabolic rates will then be 
adjusted for weight and lean body mass and be compared between PWS participants and 
controls.  
 
3.6: Ethical Approval 
The study has been approved by the HREC of the University of Queensland (Reference 
No. 2010000367) and Mater Health Services (Reference No. 1654C).  
 
3.7: Results 
16 children with PWS and 16 controls were recruited to the study. The median age of the 
PWS cohort was 9.32 years (Inter quartile range 5.29) and due to difficulty in recruiting 
matched controls, older volunteers were accepted. As a result, the controls’ median age 
was 12.16 years (inter quartile range 6.12, p = 0.078). The PWS group comprised of 16 
genetically confirmed individuals (nine females and seven males) and the control group 
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had 16 volunteers (six females and 10 males). Apart from three of the controls, no other 
participants in both PWS and controls were in puberty. Three of the PWS participants were 
on stable thyroxine therapy for central hypothyroidism. Upon download, there was no 
Actiheart recording for three of the PWS participants. This is probably due to poor contact 
of the electrode to the skin likely due to the habitual skin picking in PWS patients. The 
PWS participants are shorter compared to the controls. The median height Z score for 
PWS group was -0.39 (IQR 1.45) while that of the controls was 1.03 (IQR 1.61, p 0.049). 
The weight Z score in PWS group was 1.05 (IQR 1.62) and for the controls, 1.26 (IQR 
1.32). The difference between groups did not reach statistical significance (p value of 
0.54). The median BMI Z score in PWS group was 1.50 (IQR 1.39) and the control group 
was 1.10 (IQR- 1.11, p = 0.423). The lean mass in significantly lower in PWS group 
compared to the control group (26.00%, IQR 12.48 and 44.84%, IQR 20.85, p= 0.013). 
Similarly, waist and height ratio as an indicator of adiposity, trends to be higher in PWS 
cohort. The median waist and height ratio in PWS group was 0.55 (IQR 0.27) and that of 
the control group was 0.5 (IQR 0.1, p = 0.055). The PWS participants were treated with 
growth hormone and had plasma IGF1 level within normal range in female PWS 
participants and slightly higher than normal upper limit in males. The mean (SD) plasma 
IGF1 level for the whole group was 48.7 (28.2) nmol/l. The mean (SD) IGF1 level for male 
PWS participants was 47.6 (29.5) nmol/l (reference range: 34.9-45.2 nmol/l) and that of 
female participants was 47.6 (28.7) nmol/l (reference range: 33.2- 54.4). 
 
Table 15: Comparison of characteristics of the PWS and control groups 
 PWS Control P 
Age (Yr) 
Median (IQR) 
9.32 (5.29) 12.16 (6.12) 0.078 
Height Z score 
Median (IQR) 
-0.39 (1.45) 1.03 (1.61) 0.049 
Weight Z score 
Median (IQR) 
1.05 (1.62) 1.26 (1.32) 0.545 
BMI Z score 
Median (IQR) 
1.50 (1.39) 1.10 (1.11) 0.423 
Waist to height ratio 
Median (IQR) 
0.55 (0.27) 0.50 (0.1) 0.055 
Lean mass % 
Mean (SD) 
26.00 (12.48) 44.84 (20.85) 0.013 
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Total energy expenditure is strongly correlated to body weight and fat free mass (r= 0.91 
and 0.86 respectively, p< 0.001 in both models). Similarly resting energy expenditure is 
positively correlated to weight and fat free mass (r= 0.935 and 0.94 respectively, p< 0.001 
in both models). Correlation between activity associated energy expenditure and weight or 
fat free mass did not reach statistical significance. The correlation coefficient was 0.31 for 
activity associated energy expenditure and weight (p- 0.13) and 0.18 for fat free mass (p= 
0.38). Non- exercise associated thermogenesis and weight is positively correlated and the 
coefficient is 0.39 (p= 0.048) and for fat free mass is 0.26 (p= 0.19).  
Moreover, total energy expenditure and resting energy expenditure are positively 
correlated to age of the participants (r= 0.72 and 0.80, p< 0.001 for both). Both activity 
associated and non- exercise associated thermogenesis are not significantly correlated to 
age (r= 0.13 and 0.16, p= 0.54 and 0.43 respectively). 
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Figure 18: Comparison of EE adjusted for weight by log- log regression in PWS and 
control groups. The Y axis is weight adjusted EE (Kcal/kg) and X axis is body weight (kg). 
Figure A: TEE, Figure B: REE, Figure C: AAT and Figure D: NEAT 
 
 
Figure A: 
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Figure B: 
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Figure C: 
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Figure D: 
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Figure 19: Comparison of EE adjusted to fat free mass by log- log regression in PWS and 
control groups. The Y axis is FFM adjusted EE (Kcal/kg) and X axis is fat free mass. 
Figure A: TEE, Figure B: REE, Figure C: AAT and Figure D: NEAT 
 
Figure A: 
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Figure B: 
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Figure C: 
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Figure D: 
 
 
 
Table 17:  
Comparison of weight adjusted EE in PWS and control groups. Mean value in Kcal/kg 
(Standard Deviation). *p<0.01 and **p<0.02 difference between 2 groups 
 PWS Control 
TEE/ Wtp 
 
287.93* 
(32.12) 
432.58 
(38.66) 
REE/Wtp 
 
183.05** 
(12.62) 
200.48 
(18.07) 
AAT/Wtp 
 
98.20* 
(41.21) 
296.87 
(97.22) 
NEAT/Wtp 
 
87.96* 
(42.08) 
221.58 
(79.94) 
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Table 18: 
Comparison of fat free mass adjusted EE in PWS and control groups. Mean value in 
Kcal/kg (Standard Deviation) *p<0.01 for difference between 2 groups 
 PWS Control 
TEE/FFMp 
 
364.47* 
(51.05) 
560.80 
(62.72) 
REE/FFMp 
 
216.25* 
(16.53) 
249.92 
(21.76) 
AAT/FFMp 
 
135.27* 
(59.26) 
416.07 
(140.26) 
NEAT/FFMp 
 
122.16* 
(62.95) 
235.25 
(88.99) 
 
 
The total daily energy expenditure, REE, AAT and NEAT adjusted to weight are lower in 
the PWS group than the control group. The mean (SD) TEE adjusted for weight was 
287.93 (32.12) Kcal/ kg in PWS group and 432.58 (38.66) Kcal/ Kg for the control group 
(p< 0.01).  The mean (SD) REE adjusted for weight for PWS group was 183.05 (12.62) 
Kcal/ Kg whereas that of control group was 200.48 (18.07) Kcal/ kg (p<0.001). Both the 
weight adjusted overall activity associated energy expenditure and non- exercise 
associated thermogenesis were lower in PWS group compared to the controls [96.20 
(41.21) Kcal/ kg vs. 296.87 (97.22) Kcal/ kg, and 87.96 (42.08) Kcal/ kg vs. 221.58 (79.94) 
Kcal/ kg respectively] (p<0.01). 
When the energy expenditures were adjusted for the fat- free mass, lower total and 
differential energy expenditure were again `observed in PWS group. The mean (SD) TEE 
adjusted for fat- free mass in PWS group was 364.47 (51.05) Kcal/ Kg and in control group 
was 560.80 (62.72) Kcal/ kg (p<0.01). The mean (SD) fat- free mass adjusted REE was 
216.26 (16.53) Kcal/ Kg in PWS and 249.92 (21.76) Kcal/ Kg in control group (p<0.01). 
When adjusted for fat- free mass, the activity associated energy expenditure was 135.27 
(59.26) Kcal/ Kg in PWS group and 416.07 (140.26) Kcal/ Kg in control group (p<0.01). 
The non- exercise associated thermogenesis in PWS group was 122.16 (62.95) Kcal/ Kg 
and 235.25 (88.99) Kcal/ kg in control group (p<0.01).  Using our arbitrary definition of 
exercise, no participant in PWS group had any recording of physical activity that met the 
definition.  
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Correlation between fasting acyl ghrelin and energy expenditures does not show any 
relation. The correlation coefficients between fasting acyl ghrelin and TEE is -0.054 (p= 
0.87), REE is -0.1 (p= 0.76), AAT is 0.031 (p= 0.92), and NEAT is 0.056 (p= 0.86). The 
correlation coefficients between percent change in pulse rate at 30 sec after standing, a 
marker for sympathetic nervous function, and EE are as follow. With TEE is 0.13 (p= 0.69), 
REE, -0.05 (p= 0.87), AAT, 0.32 (p= 0.32), and NEAT, 0.30 (p= 0.35). 
 
3.8: Discussions 
Similar to the available evidence (Bernstein, Thornton et al. 1983, Garby, Garrow et al. 
1988, Welle and Nair 1990, Cunningham 1991, Goran and Sun 1998), our data showed 
that the total and resting energy expenditure were positively correlated to weight and fat 
free mass. Although positive correlation of non- exercise associated thermogenesis and 
weight was statistically significant, the correlation between fat free mass was not 
statistically significant.   
The overall TEE, REE, AAT and NEAT in PWS group when adjusted to both body weight 
and fat free mass were lower than the control group. Better REE or activity- associated EE 
have been reported in PWS (van Mil, Westerterp et al. 2000, Goldstone, Brynes et al. 
2002) but no data is available for in NEAT, or TEE adjusted for weight or fat free mass in 
PWS. To our knowledge, our findings are the first to compare adjusted NEAT, AAT and 
TEE of PWS patients to unaffected individuals. 
It has been proven that growth hormone therapy improves the energy expenditure and 
body composition (Carrel, Myers et al. , Sode-Carlsen, Farholt et al. , Brambilla, Bosio et 
al. 1997, Nakazato, Murakami et al. 2001, Carrel, Myers et al. 2002, Mogul, Lee et al. 
2008). Despite of the growth hormone therapy in PWS participants achieving optimal level 
of plasma IGF1, the energy expenditures remained low in our PWS group.  
An animal study showed that when rats were treated with intracerebroventricular injections 
of ghrelin, NPY and Argp there was significant reduction in locomotor activity of the 
animals compared to the controls that received vehicle (St-Pierre, Karelis et al. 2004, 
Tang-Christensen, Vrang et al. 2004). However, there was no significant correlation 
between fasting acyl ghrelin and activity associated or non- exercise associated 
thermogenesis. The relation between TEE, REE, AAT and NEAT, and percent change of 
pulse rate on standing for 30 sec at fasting state did not reach statistical significance. 
Nevertheless, the autonomic nervous system has crucial role in controlling thermogenesis 
and our findings of dysautonomia in PWS may play a role in low EE. A larger sample size 
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than 16 participants in each cohort is needed to identify significant correlation between 
ANS function and EE. 
Dysautonomia in PWS patients may have impaired the mitochondrial functions as ANS 
has been shown to have influence mitochondrial functions (Smith and Horwitz 1969, Zhao, 
Cannon et al. 1997, Jezek 2002, Sluse, Jarmuszkiewicz et al. 2006). In an animal study 
using electron microscope, PWS model mice with imprinting centre defect were found to 
have abnormal mitochondrial proliferation, swollen and disorganized mitochondria with 
disrupted membrane in skeletal and cardiac muscles, compared to the littermates (Yazdi, 
Su et al. 2013). Moreover, the gene expression in the study showed the PWS mice had 
up- regulated Mrpl15 (mitochondrial ribosomal protein L15) and down- regulated Alas1 
(aminolevulinic acid synthase 1) genes in brain tissues. Mrpl15 is responsible for 
mitochondrial protein synthesis (Kenmochi, Suzuki et al. 2001) and Alas1, rate limiting and 
first enzyme in haem biosynthesis (Mason, Fan et al. 2009). In the muscle tissues of the 
PWS mice, Yazdi et al. discovered down- regulation of Bdh (3- hydroxybutyrate 
dehydrogenase), and Mte1 (mitochondrial acyl- co A thioesterase 1) (Yazdi, Su et al. 
2013). Both genes are involved in mitochondrial fatty acid oxidation and are important for 
energy production. Acadl (acetyl- coenzyme A dehydrongenase, long- chain) was also 
down regulated in PWS mice muscle compared to their littermates in the study. Acadl 
belongs to the acyl-CoA dehydrogenase family of mitochondrial flavoenzymes involved in 
fatty acid and branched chain amino acid metabolism. In the PWS-IC model, there are 
abnormal mitochondrial genes, abnormal mitochondria and mitochondrial proliferation. 
Therefore, at least in PWS-IC mice model, there is evidence that energy production is low 
as a result of mitochondrial abnormalities (Yazdi, Su et al. 2013). A case report described 
a two-year-old girl with PWS who has a novel mutation of MTCYB gene that is responsible 
for mitochondrial complex III deficiency (Yis, Ezgu et al. 2014).  MTCYB is mitochondrial 
cytochrome b gene, which is not part of PWS gene region. The affected PWS patient in 
the report had hypotonia, hepatosteatosis, and episodes of lactate acidosis for which she 
was treated with Carnitine and Coenzyme Q 10 (CoQ-10).  CoQ-10 is a lipid soluble 
component of cell membranes which is responsible for electron transfer from complex I 
and II to complex III on the inner mitochondrial membrane (Bentinger, Tekle et al. 2010). It 
is important for mitochondrial function and energy production. There is no concrete 
evidence suggesting CoQ-10 treatment is beneficial in PWS (Eiholzer, Meinhardt et al. 
2008). Butler et al. measured plasma CoQ-10 and reported it was lower in PWS compared 
to the lean controls but not different to obese controls (Butler, Dasouki et al. 2003). 
Another study also reported blood CoQ-10 level was not different to obese and lean 
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controls. But PWS group had higher carnitine esters and ester- to- free carnitine ratios 
than the controls (Miller, Lynn et al. 2011).  Carnitine is a cofactor for the transport of fatty 
acids into the mitochondria for β- oxidation. High ester- to- free carnitine ratio occurs when 
mitochondrial energy production is impaired (Calvani, Reda et al. 2000).  
Another probable reason for low energy expenditure is the long non- coding RNA 
Snord116 in PWS gene region (Zhang, Bouma et al. 2012, Powell, Coulson et al. 2013, 
Powell, Coulson et al. 2013). Its expression was prominent in hypothalamic regions that 
control bodily homeostasis such as food intake, blood pressure and regulate energy 
balance (Zhang, Bouma et al. 2012). Snord116 expression was found to be highly in para- 
ventricular nuclei, ventro- medial nuclei and particularly very high in the Arcuate nuclei 
which are important feeding circuitry. Zhang et al. speculated that Snord116 might be the 
underlying cause for the phenotype of PWS. It was supported by a case report of an 
individual with a micro- deletion of snoRNA region of 15q11.2 who has features of PWS 
(Sahoo, del Gaudio et al. 2008). If it is proven to be true, PWS will be the first human 
genetic condition to prove that non- coding RNAs are as important as protein coding RNAs 
as Mattick hypothesized some years ago (Mattick 2005). In another study, Powell et al. 
used fluorescence in- situ hybridization probes targeting the splice junction of lncRNA such 
as 116HG on mice brain.  It revealed distinct nuclear clouds and it was observed on 
hypothalamus as well as forebrain, hindbrain, cortex, hippocampus, and cerebellum 
(Powell, Coulson et al. 2013). Snord116 deleted mice, when compared to the littermates, 
were found to have abnormal gene important for signal transduction and metabolic 
regulation such as MTOR (Mechanistic target of Rapamycin). Brain slices were stained for 
mTOR protein and there was up-regulation of mTOR in cortex but not in hippocampus. 
Circadian clock regulation in hypothalamic nuclei, such as supraoccular nuclei, controls 
mTOR activity (Cao, Anderson et al. 2011). Powell’s study did not prove the pathogenicity 
of snord116 in PWS but provided the novel explanation of loss of snord116. It will be very 
interesting to identify the RNAs generated from the snord116 locus absent in PWS. 
Our data showed low energy expenditures captured on Actiheart among PWS participants 
who inherently have hypotonia (Prader, Labhart et al. 1956, Eiholzer 2005, Cassidy and 
Driscoll 2009), sedentary life style (Davies and Joughin 1993) and a degree of skeletal 
abnormality (West and Ballock 2004, Kroonen, Herman et al. 2006). Being inactive can 
cause poorer mitochondrial functions. Exercise is known to increase mitochondrial 
oxidative capacity and contents (Zoll, Sanchez et al. 2002). Zoll et al. studied human 
skeletal muscle’s mitochondrial respiration functions among athletic, active, and sedentary 
individuals. The athletic individuals had better mitochondrial respiration rate, oxidative 
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function and more efficient coupling. The authors compared and found that ADP- 
stimulated mitochondrial respiration before exercise (Ѷ0) was similar in all groups but after 
exercise (Ѷmax) it was significantly higher in athletic group indicating better mitochondrial 
respiration. Moreover, Ѷmax was positively correlated to ѶO2 max. The study also examined 
kinetics of ADP (Km constant value) in skeletal mitochondria. Athletic individuals had 
higher value of Km indicating better mitochondrial oxidative function. In animal studies 
(Veksler, Kuznetsov et al. 1995, Kuznetsov, Tiivel et al. 1996), higher Km was seen in 
oxidative muscles and low value in glycolytic muscles. Since individuals with PWS do not 
exercise regularly, their mitochondria would not have good respiration rate, oxidative 
function or efficient coupling resulting in poor energy expenditure. 
In summary, PWS group had lower total, resting and activity associated energy 
expenditure in our study. Dysautonomia may be the cause for impairment in mitochondrial 
function resulting in lower resting and non- exercise associated energy expenditures 
leading to lower total energy expenditure. Non- coding RNA (Snord116) from the PWS 
region and fasting hyperacylghrelinaemia may have a role in impairment of mitochondrial 
functions. Sedentary nature of children with PWS may also have contributed to the poor 
mitochondrial functions and low energy expenditure as a result. 
 
3.9: Conclusions 
We found that the TEE, REE, AAT and NEAT were lower in children with PWS compared 
to the controls. Despite of the growth hormone therapy, which generally increases energy 
expenditure in PWS patients, the overall energy output was found to be lower than the 
controls. To our knowledge our study is the first to examine TEE and NEAT in PWS.  A 
number of possible causes such as dysautonomia, high fasting plasma acyl ghrelin level, 
snord116 gene and mitochondrial abnormalities suggested by PWS-IC deleted animal 
model may have influence on low energy expenditure in participants with PWS. Our PWS 
cohort had low EE and low lean mass although being treated with GH. They will benefit 
from higher GH dose and increased physical activity such as regular exercise and 
incidental activity (NEAT). 
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Chapter 4: 
Conclusions 
We conclude that there is dysautonomia in PWS. Our cardiovascular data suggests poor 
sympathetic nervous function; and the gastrin and catecholamine data pointed to poor 
vagal function. There are two probable explanations for poor sympathetic outflow and poor 
vagal functions. Firstly, reduced GABA-A receptor number and probably its action in PWS 
as a result of the deleted 3, 5, and 3 subunit genes of GABA-A receptor; and secondly, 
probable exaggerated GABA-B action due to compensatory hyper-- amino- butyric- 
acidaemia and normal GABA-B receptors. GABA is the key neurotransmitter between 
Nucleus Tractus Solitarius and C1 neurons that connect to the thoracic spinal cord that 
sends efferent neurons to sympathetic ganglions. GABA is generally an inhibitory 
neurotransmitter and GABA dysfunction may be the cause of poor vagal inhibitory function 
that lead to high post-prandial plasma gastrin production, and increased catecholamine 
production from adrenal medulla probably by increased chromaffin cells gap junction 
communications.  
Poor sympathetic and parasympathetic nervous functions per se can lead to obesity. Bray 
et al. proved Mona Lisa hypothesis which means “ Most obesities known are low in 
sympathetic activity” (Bray 1991). Bray et al. published a number of studies on relationship 
between sympathetic nervous system and food intake (Bray 1991, Bray and York 1998, 
Bray 2000) and reported that there is inverse relation between sympathetic nervous 
system and food intake. Findings of Bray et al. were supported by further reports of acute 
and chronic increase in sympathetic outflow, as a result of later hypothalamic lesion, had 
led to weight loss in the study animals (Arase, Sakaguchi et al. 1987). Monda et al. 
reported pre-menopausal women with poor ANS function, based on heart rate variability, 
were obese (Monda, Messina et al. 2006). Therefore our finding of dysautonomia itself can 
cause increased food intake or energy intake, and obesity in PWS. 
Dysautonomia may also have a causal role in our finding of high fasting plasma acyl 
ghrelin in PWS participants. To our knowledge, rapid reduction in plasma acyl ghrelin 
among PWS participants after meal to similar levels to the control is a novel finding. Since 
acyl ghrelin in PWS participants is well suppressed after a meal, their poor satiation may 
be not be induced by acyl ghrelin.  
In our study, the PWS participants had lower total, resting, activity associated, and non-
exercise associated energy expenditure compared to the controls. Despite the adequate 
growth hormone therapy that maintained appropriate blood IGF1 level, the PWS 
participants had lower energy expenditure. The growth hormone dosage for PWS patients 
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recommended by Australian Pharmaceutical Benefit Scheme is lower than the dosage 
used elsewhere in the world. It may be the reason for our finding of low energy 
expenditure in PWS unlike previous reports of growth hormone treated PWS patients 
having resting energy expenditure similar to controls. To our knowledge, we are the first to 
report lower total energy expenditure and non- exercise associated thermogenesis in the 
PWS participants than the controls. Again dysautonomia in PWS participants may have 
caused low resting and non- exercise associated energy expenditure. High fasting acyl 
ghrelin and snord116, a long non- coding RNA present in the PWS gene region, may also 
have contributed to it. Animal model of PWS, PWS-IC deleted mice, had abnormal 
mitochondrial proliferation; swollen and disorganized mitochondria with disrupted 
membrane, and abnormal expressions of mitochondrial genes. However, no such findings 
have been replicated in human model or other PWS mice models.  
Our finding of dysautonomia and high fasting acyl ghrelin may be one of the causes of 
increased food intake or increased energy intake in PWS participants. Despite of growth 
hormone therapy, the energy expenditures of PWS participants were lower than the 
controls. Hence, there is imbalance between energy gained and energy utilized which 
leads to obesity in PWS. GABA dysfunction as a result of attenuated GABA-A receptor 
action and probable increased GABA-B receptor function, at the level of Nucleus Tractus 
Solitarius may be the underlying pathological cause of imbalance between energy gain 
and expenditure which leads to development of obesity in PWS. 
 
Strengths of the study 
Most of the available literatures on ANS in PWS were based on cardiovascular functions. 
Our research studied not only the cardiovascular functions but also the production of gut 
hormone gastrin and adrenal catecholamine to assess ANS functions in PWS. We also 
report ANS data after stimulating by a mixed meal. Therefore our data provides more 
comprehensive ANS profiles in PWS.  
We used a protease inhibitor in plasma sample preparation for measurement of acyl 
ghrelin. It reduced the chance of degradation of acyl ghrelin by protease and allowed more 
accurate measurement of the peptide. To our knowledge, the post-prandial suppression of 
acyl ghrelin to a level similar to the controls at 60 and 120 minutes post meal is a novel 
finding.  
We report adjusted total, resting, activity associated and non-exercise associated energy 
expenditures in children with PWS. Our data describes comprehensive nature of 
thermogenesis in children with PWS. 
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Limitations 
Our study has a number of limitations. Government subsidized growth hormone therapy 
became available for all children under 18 years with PWS before the recruitment. 
Therefore, all PWS participants were already on growth hormone therapy at recruitment 
which may be a limitation of our study. Due to difficulty in recruiting controls, older 
participants were accepted as controls. Actiheart data from 3 PWS participants were lost 
likely due to poor contact of the electrode as a result of skin picking on the adhesive tapes 
on the chest wall. The number of participants may not be enough to show any correlation 
between ANS functions, acyl ghrelin levels and energy expenditures in our study. Our 
sample size of 16 may be under-powered to show the correlation between ANS function 
and EE. 
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Chapter 5 
Future Directions 
5.1: Plasma GABA level 
PWS gene region contains expression of subunits that make up gamma amino butyric acid 
receptor A (Wagstaff, Knoll et al. 1991) and positron emission tomography scan showed 
GABA- A receptor number in brain is low in patients with PWS (Lucignani, Panzacchi et al. 
2004). Plasma GABA level was significantly higher in patients with PWS supporting 
deficiency of GABA-A receptors (Ebert, Schmidt et al. 1997). The historical evidence of 
dysfunction of GABA system in PWS can explain our finding of dysautonomia and higher 
fasting acyl ghrelin in children with PWS.  We plan to measure GABA level in the leftover 
fasting blood sample to complement our current findings.  
 
5.2: Ghrelin auto- antibody in PWS 
In our findings, despite the fact that children with PWS had higher fasting acyl ghrelin 
which got suppressed to a level similar to the controls at 60 and 120 minutes after meal, 
their waist- to- height ratio was higher and lean body mass was lower. High fasting acyl 
ghrelin may stimulate appetite but its post- prandial levels did not support the typical poor 
satiation and hyperphagia seen in PWS (Prader, Labhart et al. 1956, Holland, Treasure et 
al. 1993). I further hypothesize that there must be a contributory mechanism or different 
mechanism controlling appetite in PWS other than ghrelin level alone. 
Recently autoantibody against ghrelin was discovered in healthy human and in those with 
anorexia nervosa (Fetissov, Hamze Sinno et al. 2008, Terashi, Asakawa et al. 2011). 
Fetissov et al. identified IgG and IgA against leptin, ghrelin, peptide YY, and neuro-peptide 
Y in healthy women. In another study, anti- ghrelin IgG was identified and it was mainly an 
immune complex with desacyl ghrelin in patients with anorexia nervosa (Terashi, Asakawa 
et al. 2011). Auto- antibodies for acyl ghrelin were decreased and it resulted in higher 
unbound acyl ghrelin suggesting phenomenon of ghrelin resistance in malnourished 
patients with anorexia nervosa. The role of anti- ghrelin autoantibody on food intake was 
tested in an animal study (Takagi, Legrand et al. 2013). Free feeding rats received intra- 
peritoneal injection of ghrelin alone or together with anti- ghrelin antibodies from obese, 
anorexic and lean participants. Rats that received ghrelin and anti- ghrelin antibodies from 
obese subjects had increased food intake. Furthermore, the authors tested whether the 
ghrelin IgG prevents ghrelin degradation. When ghrelin alone is incubated at 37°C, its 
concentration decreased significantly indicating rapid degradation but when incubated 
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together with ghrelin IgG extracted from either controls, anorexics, or obese patients, most 
of the level initially added could be detected in-vitro.  
GABA- A receptor subunits RNA expression was noted in murine peripheral macrophages 
and modulates their IL 6 and IL 12 production (Reyes-Garcia, Hernandez-Hernandez et al. 
2007). Moreover, GABA-A receptors mediate inhibitory response on T lymphocytes (Tian, 
Chau et al. 1999). Having deficiency of GABA- A receptors in PWS, there may be 
increased risk of poor immune surveillance and autoimmunity (Tian, Lu et al. 2004).  
Therefore, it is my hypothesis that in PWS, due to GABA- A receptor deficiency, there is 
poor T cell immune surveillance. It increases risk of formation of ghrelin auto- antibody 
which prevents degradation of orexigenic ghrelin that in turn stimulates appetite. I have a 
plan to measure and compare ghrelin IgG in leftover PWS and control samples. 
 
5.3: Nesfatin-1 
Nucleobindin 2 (NUCB2)- encoded satiety and fat- influencing protein 1 (nesfatin-1) 
inhibits food intake upon injection to ventricles in animal studies (Oh, Shimizu et al. 2006, 
Shimizu, Oh et al. 2009). Only the Mid- segment of nesfatin-1 contains potent anorexigenic 
effect compared to N- segment or C- segment (Shimizu, Oh et al. 2009). The anorexigenic 
effect of mid- segment of nesfatin-1 is independent of leptin pathway as reduced food 
intake was still observed in db/db mice and overfed obese mice (Shimizu, Oh et al. 2009). 
Central injection of nesfatin-1 increases c-fos expression in Paraventricular nucleus of 
hypothalamus and Nucleus Tractus Solitarius. 
In another animal study using immunohistochemistry, co-localization of ghrelin and 
nesfatin-1 was observed in hypothalamus and anterior intestine of the goldfish (Kerbel and 
Unniappan). In the same study, intracerebroventricular injection of nesfatin-1 and ghrelin 
reduced the mRNA expression of pre-proghrelin and NUCB2 in hypothalamus 
respectively, indicating reverse relationship between the two peptides (Kerbel and 
Unniappan). Maejima et al. elegantly described nesfatin-1 regulates oxytocinergic 
signaling in hypothalamus and Nucleus Tractus Solitaries which in turn stimulates 
melaocortin pathway to induce anorexia independent of leptin (Maejima, Sedbazar et al. 
2009).  
Swaab et al. performed post- mortem examination on PWS brain and reported that the 
number of oxytocin containing neurons is low (Swaab, Purba et al. 1995, Swaab 1997). 
Therefore, it is my hypothesis that in PWS, anorexigenic Nesfatin-1 may be low resulting in 
reduced oxytocin expression in hypothalamus and poor satiation. To date, little is known 
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about plasma profile of nesfatin-1 in relation to a meal in healthy human or nesfatin-1 
status in PWS where satiety is not commonly achieved after a meal. 
I plan to measure the fasting plasma Nesfatin-1 levels by enzyme linked immunoassay 
and compare the levels between the PWS and control groups. A financial grant has been 
obtained already and an ethics application is in progress for the projects. 
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